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ttp://dx.doi.org/10.1016/j.jmoldx.2013.03.001Objective: To establish evidence-based recommendations for the molecular analysis of lung cancers that are
required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested,
and when and how testing should be performed. Participants: Three cochairs without conﬂicts of interest were
selected, one from each of the 3 sponsoring professional societies: College of American Pathologists, Inter-
national Association for the Study of Lung Cancer, and Association for Molecular Pathology. Writing and
advisory panels were constituted from additional experts from these societies. Evidence: Three unbiased
literature searches of electronic databases were performed to capture published articles from January 2004
through February 2012, yielding 1533 articles whose abstracts were screened to identify 521 pertinent articles
that were then reviewed in detail for their relevance to the recommendations. Evidencewas formally graded for
each recommendation. Consensus Process: Initial recommendationswere formulated by the cochairs andpanel
members at a publicmeeting. Each guideline sectionwas assigned to at least 2 panelists. Drafts were circulated
to the writing panel (version 1), advisory panel (version 2), and the public (version 3) before submission
(version 4). Conclusions: The 37 guideline items address 14 subjects, including 15 recommendations (evidence
grade A/B). Themajor recommendations are to use testing for EGFRmutations andALK fusions to guide patient
selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)
inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking
history, or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive
tests. As scientiﬁc discoveries and clinical practice outpace the completion of randomized clinical trials,
evidence-based guidelines developed by expert practitioners are vital for communicating emerging clinical
standards. Already, new treatments targeting genetic alterations in other, less common driver oncogenes are
being evaluated in lung cancer, and testing for these may be addressed in future versions of these guidelines.
(J Mol Diagn 2013, 15: 415e453; http://dx.doi.org/10.1016/j.jmoldx.2013.03.001)See next page for support and disclosure information.
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Lindeman et alBackground: EGFR Mutations and ALK FusionsLung cancer is the leading cause of cancer-related mortality,
accounting for approximately 1.4 million deaths per year
worldwide and approximately 160,000 deaths per year in
the United States, which is approximately 25% to 30% of all
US cancer deaths and more than the next 3 cancers (colon,
prostate, breast) combined.1 Fortunately, the past decade has
seen major advances in our understanding of the patho-
genesis and management of lung cancers, adenocarcinoma
in particular. Speciﬁcally, the discovery of the biological
and therapeutic importance of acquired genetic alterations in
2 genes that encode pharmacologically targetable tyrosine
kinases involved in growth factor receptor signaling,
epidermal growth factor receptor (EGFR) and anaplastic
lymphoma kinase (ALK ), has changed the way these
cancers are diagnosed and treated.
As geﬁtinib and erlotinib, small-molecule competitive
inhibitors of the EGFR tyrosine kinase, were being evalu-
ated in clinical trials of advanced-stage lung cancer in the
early part of the last decade, unusual prolonged responses to
these medications were recognized in a subset of patients.2
This unusual clinical behavior, not seen previously with
standard chemotherapy, led to investigations that identiﬁed
a correlation between activating somatic mutation in the
EGFR gene and clinical response to geﬁtinib and erlotinib.
This initial exciting observation has led to sustained and
continuing laboratory and clinical investigations into the
mechanism and clinical consequences of EGFR mutations
in lung cancer. In unselected advanced nonesmall cell lung
cancer (NSCLC) patients, geﬁtinib and erlotinib produce
response rates of 8% to 9%, with a median time to
progression of 2.2 months to 3.0 months.3 In contrast,
advanced NSCLC patients selected on the basis of acti-
vating EGFR mutations in their tumors show response rates
(RRs) of 68%, with a mean progression-free survival (PFS)
and time to progression of 12 months (Table 1).4e6
In 2009, the ﬁrst randomized clinical trial (the Iressa Pan-
Asia Study [IPASS]) showed that, for advanced NSCLC
patients with an activating EGFR mutation, initial treatment
with an EGFR tyrosine kinase inhibitor (TKI) was superior
to standard platinum-based chemotherapy.7 In this study,
which enrolled East Asian patients with stage IIIB/IV lungSupported by the College of American Pathologists (CAP), International
Association for the Study of Lung Cancer (IASLC), and Association for
Molecular Pathology (AMP); no industry funds were used in the devel-
opment of the guideline.
This guideline was developed through collaboration between CAP,
IASLC, and AMP and has been jointly published by invitation and consent
in the Archives of Pathology & Laboratory Medicine, The Journal of
Molecular Diagnostics, and the Journal of Thoracic Oncology. It has been
edited in accordance with standards established at the Archives of
Pathology & Laboratory Medicine.
Standard of practice is not being deﬁned, and there may be alternatives.
See Disclaimer for further details.
Disclosures: For author conﬂict of interest disclosures, see Appendix.
416adenocarcinoma who never smoked tobacco (or only
smoked lightly), the patients whose tumors contained an
activating EGFR mutation and who received geﬁtinib had
a signiﬁcantly longer PFS than those receiving chemo-
therapy (hazard ratio [HR] for progression or death, 0.48;
P < 0.001).7 Subsequently, 5 additional randomized con-
trolled trials conﬁrmed this association between activating
EGFR mutations and objective response to geﬁtinib and/or
erlotinib therapy (Table 2). However, despite these im-
pressive differences in PFS, no study has shown an
advantage in overall survival for EGFR-mutationebearing
patients treated initially with an EGFR TKI in comparison
to chemotherapy. This is likely to be at least partly due to
the crossover design of these studies, in that a large fraction
of the patients with EGFR-mutated tumors treated initially
with chemotherapy crossed over to the EGFR TKI treat-
ment arm, confounding the interpretation of overall survival
data.
Three years after the initial discoveries of EGFR
mutations in lung cancer, in 2007, Soda and co-workers8
reported that an inversion on chromosome arm 2p
resulted in the creation of an EML4-ALK fusion gene in
lung cancer. The fusion gene was identiﬁed in 5 of 75
(7%) NSCLC patients examined. Subsequent studies have
indicated that the prevalence of this gene fusion event is
about 2% to 7% of all NSCLCs seen in the United States,
with enrichment in adenocarcinomas in never smokers or
light smokers.9e20 Testing for this ALK gene fusion has
been facilitated by the commercial availability of a dual-
probe “break-apart” ﬂuorescence in situ hybridization
(FISH) assay for ALK rearrangements that was already in
clinical use to detect ALK fusions in lymphomas and
certain sarcomas.15 A recent report of a large clinical
series indicated that ALK rearrangements were seen in
about 5% of 1500 NSCLC patients screened.13 Moreover,
ALK rearrangement-positive patients treated with a novel
ALK inhibitor, crizotinib, showed an overall response
rate of 57%, with 72% having a PFS of 6 months or
greater.13 The US Food and Drug Administration (FDA)
has approved crizotinib for advanced-stage, ALK-positive
lung cancer as is also recommended by recent guidelines
from professional organizations, including the American
Society of Clinical Oncology (ASCO), European Society
for Medical Oncology, and National Comprehensive
Cancer Network (NCCN).
Given the considerable published data on EGFR-mutated
lung cancer and the rapid pace of work on ALK, represen-
tatives of 3 professional organizations with interest in the
diagnosis and management of lung cancerdthe College of
American Pathologists (CAP), the International Association
for the Study of Lung Cancer (IASLC), and the Association
for Molecular Pathology (AMP)dconvened to systemati-
cally review the published data and develop evidence-based
recommendations for the molecular testing of lung cancers
for these 2 critical predictive biomarkers in a clinical prac-
tice guideline (CPG).jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Different Outcomes in All Stages of NoneSmall Cell Lung Cancer Patients With and Without EGFR Mutations, Treated with Tyrosine
Kinase Inhibitor
Outcome
Mean  SD Percentage
n (N) WMD (95% CI) RR (95% CI) P value
EGFR
mutation
positive
EGFR
mutation
negative
EGFR
mutation
positive
EGFR
mutation
negative
Response rate, %* 68 11 51 (3644) 5.16 (4.41e6.04) <0.001
Disease control rate, %y 86 42 28 (2204) 1.99 (1.73e2.29) <0.001
Time to progression/
progression-free
survival, moz
12.0  7.86 3.4  2.59 27 (2347) 8.66 (6.31e11.00) <0.001
Median survival time, mox 23.3  18.4 12.1  13.9 27 (2489) 10.66 (8.36e12.96) <0.001
*References 7, 17, 28, 48, 53, 56, 58, 110, 129, 133, 170, 191e198, 202, 211, 250e278.
yReferences 7, 17, 53, 56, 115, 129, 133, 191, 193e195, 202, 250e254, 258, 259, 261, 266, 267, 273e275, 277e279.
zReferences 17, 28, 53, 56, 58, 129, 170, 185, 191, 193, 195, 201, 211, 250e252, 254, 255, 261e263, 266, 267, 275e278.
xReferences 17, 28, 53, 56, 90, 129, 170, 183, 184, 191, 193, 197, 253e255, 258, 259, 261, 262, 266, 267, 270e272, 276e278.
CI, conﬁdence interval; n, number of studies; N, number of patients; RR, relative risk; SD, standard deviation; WMD, weighted mean difference.
Lung Cancer Molecular Testing GuidelinesCPGs are systematically developed statements intended to
assist practitioners and patients in making decisions about
appropriate health care options for speciﬁc clinical circum-
stances. Attributes of good CPGs include validity, reliability,
reproducibility, clinical applicability, clinicalﬂexibility, clarity,
multidisciplinary process, review of evidence, and documen-
tation. Speciﬁcally, utilization of CPG recommendations may
provide improvements in outcomes and in medical practice;
minimize inappropriate practice variation; provide decision
support tools for practitioners, a reference for medical educa-
tion, criteria for self-evaluation, and indicators and criteria for
external quality review; and assist with reimbursement and
coverage decisions. Finally, the process of CPG development
can also identify areas where further research is needed.
Clinical Practice Guideline Questions
This CPG addresses 5 principal and 14 corollary questions
regarding molecular testing in NSCLC:
I. When should molecular testing for NSCLC be performed?Tabl
Chem
Stud
EURT
OPTI
NEJ
WJTO
IPAS
LUX
Ch
The1. Which patients should be tested for EGFR mutations
and ALK rearrangements?
2. When should a patient specimen be tested for EGFR
mutations or ALK rearrangements?
3. How rapidly should test results be available?e 2 Randomized Clinical Trial Data on Epidermal Growth Factor
otherapy as First-Line Therapy for Patients With EGFR-Mutated Lun
y
Number of patients with
EGFR-mutated lung cancers
R
v
AC280 173 (86 erlotinib and 87 chemo) 5
MAL281 154 (82 erlotinib and 72 chemo) 8
00291 228 (114 gefitinib and 114 chemo) 7
G340526 117 (58 gefitinib and 59 chemo) 6
S7,90 261 (132 gefitinib and 129 chemo) 7
LUNG3282 345 (230 afatinib and 115 chemo) 5
emo, chemotherapy; HR, hazard ratio; mo, months.
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8 vs
3 vs
4 vs
2 vs
1 vs
6 vs4. How should specimens be processed for EGFR
mutation testing?
5. What are the specimen requirements for EGFR
testing?
6. How should EGFR testing be performed?
7. What is the role of KRAS analysis in selecting
patients for targeted therapy with EGFR TKIs?
8. What additional testing considerations are important
in the setting of secondary or acquired EGFR TKI
resistance?III. How should ALK testing be performed?
9. What methods should be used for ALK testing?IV. Should other genes be routinely tested in lung
adenocarcinoma?
10. Are other molecular markers suitable for testing in
lung cancer?
V. How should molecular testing of lung adenocarcinomas
be implemented and operationalized?
11. Must all adenocarcinomas be tested for both EGFR
and ALK?
12. How should EGFR and ALK results be reported?
13. How should EGFR and ALK testing be
validated?
14. How should quality assurance be maintained?eptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Versus
ncers
nse rate (EGFR TKI
s chemotherapy), %
Progression-free survival (EGFR
TKI versus chemotherapy), mo
. 15 9.7 vs. 5.2 (HR 0.37)
. 36 13.1 vs. 4.6 (HR 0.16)
. 31 10.8 vs. 5.4 (HR 0.30)
. 32 9.2 vs. 6.3 (HR 0.49)
. 47 9.5 vs. 6.3 (HR 0.48)
. 23 11.1 vs. 6.9 (HR 0.58)
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Lindeman et alMaterials and Methods
A detailed account of the methods used to create this
guideline can be found in the Supplemental Data [http://dx.
doi.org/10.1016/j.jmoldx.2013.03.001].
Panel Composition
The CAP Pathology and Laboratory Quality Center, and
representatives from the IASLC and AMP, jointly convened
an expert author panel and scientiﬁc advisory panel con-
sisting of experts in clinical pathology and oncology, and
research and development relevant to molecular testing in
NSCLC. A conference with the expert author and advisory
panels was held in December 2010, at which representatives
from industry, public health policy and regulatory affairs,
patient advocacy, and commercial drug and/or diagnostic
device manufacturers were invited to participate. Represen-
tatives from the FDA, the National Cancer Institute, ASCO,
and the NCCN attended the conference. The opinions of
panel members associated with ofﬁcial government agencies
represent their individual views and not necessarily those of
the agency with which they are afﬁliated. All members of the
expert (author) panel were required to disclose ﬁnancial and
personal conﬂicts of interest (see below).
Systematic Literature Review and Analysis
The literature search strategy involved searching the
following electronic databases from January 2004 through
February 2012: Ovid MEDLINE, Ovid MEDLINE In-
Process & Other Non-indexed Citations, and the Wiley
Cochrane Library. The following keywords and MeSH
terms were used in the search: lung neoplasms; lung cancer;
carcinoma, non-small cell lung; EGFR; epidermal growth
factor receptor; ALK; KRAS; BRAF; mutation; ampliﬁca-
tion; gene copy number; rearrangement; fusion; trans-
location; inversion; immunohistochemistry; IHC; and FISH.
All searches were limited to the English language.
Eligible Study Designs
Systematic reviews with or without metaanalyses, random-
ized controlled trials, cohort studies, case-control studies,
case series, and method comparisons were eligible for this
study. Also included were testing guidelines and proﬁciency
testing strategies of various US and international
organizations.
Inclusion Criteria
Articles were eligible for inclusion if they met the following
criteria:
1. The study compared, prospectively or retrospectively, the
sensitivity, speciﬁcity, negative predictive value, or positive
predictive value of EGFR or ALK tests for detection of an418EGFR mutation, ALK rearrangement, or response to a tar-
geted EGFR or ALK TKI; the study described technical
comparisons across various assay platforms; the study
examined potential testing algorithms forNSCLCmolecular
testing; or the study examined the correlation of EGFR or
ALK status in primary versus metastatic tumors from the
same patients.
2. The study population consisted of patients with a diag-
nosis of NSCLC.
3. The primary outcomes included the sensitivity, speciﬁcity,
positive predictive value, and negative predictive value of
tests to determine EGFR or ALK status or treatment
response, alone and in combination; concordance across
platforms; and accuracy in determining EGFR or ALK
status and beneﬁt from EGFR or ALK TKI therapy.
Exclusion Criteria
Letters, commentaries, editorials, reviews, and case reports
were excluded.
Tests Examined
Additional test methods considered included EGFR copy
number by FISH or bright-ﬁeld chromogenic in situ
hybridization, immunohistochemistry for expression of
ALK (kinase domain or carboxy-terminal) or mutated
EGFR protein, and reverse transcriptionepolymerase chain
reaction (RT-PCR) detection of EML4-ALK fusion tran-
script. Alterations in other genes, including KRAS, BRAF,
and MET, were also considered.
Outcomes of Interest
The primary outcomes of interest were the correlations between
EGFRmutation orALK rearrangement and beneﬁt from EGFR
or ALK TKI therapies, respectively. Other outcomes of interest
included accuracy in determining EGFR or ALK status,
concordance across technical platforms, sensitivity, and speci-
ﬁcity of different tests. After careful consideration of each of
these, the expert panel and advisory panel agreed that the
primary recommendations of this guideline should focus on
EGFR mutation assays and ALK FISH assays.
The panel reviewed the results of randomized controlled
trials in lung cancer, evaluating therapies targeting EGFR or
ALK, such as geﬁtinib, erlotinib, and crizotinib. The panel
also reviewed unblinded trials comparing various testing
methods, describing test characteristics, and deﬁning strat-
egies for quality assurance of testing in the literature.
Environmental Scan
At the December 2010 conference, individuals representing
regulatory agencies (FDA) also provided information about
the regulatory framework. Individuals involved with quality
assurance in the United States (CAP), the Netherlands, andjmd.amjpathol.org - The Journal of Molecular Diagnostics
Lung Cancer Molecular Testing GuidelinesCanada (Province of Ontario) also provided information
about programs to measure and improve EGFR and ALK
testing. This information was used to help the panel specify
testing requirements and exclusions, and the necessary
quality assurance monitoring that will make the testing less
variable and more accurate.
Quality Assessment and Grading of the Included
Evidence
Grading of recommendations was based on overall ratings of
individual components of the evidence, such as strength of
evidence, its consistency, clinical impact, generalizability, and
applicability to the international health care system.20e22 For
strength of the evidence, we considered the level of evidence
based on its hierarchy, number of studies and number of
patients,magnitude of effect from theweightedmean difference
or risk ratio, statistical precisionmeasured as a point estimate or
conﬁdence interval, and methodologic quality of included
studies.22 The quality of systematic reviews, randomized
control trials, and cohort studies was assessed by using the
AMSTAR (Assessment of Multiple Systematic Reviews)
instrument and SIGN (Scottish Intercollegiate Guidelines
Network) 50 checklists, respectively.23,24
The overall grade of the recommendation was obtained by
rating all components of the evidence. The overall grade
indicates the strength of the body of evidence to assist the
users of clinical practice guidelines inmaking appropriate and
informed clinical judgments.23 Grade A or B evidence
supports “recommendations,” which are generally based on
a body of evidence that can be trusted to guide clinical practice
in all or inmost situations. GradeC evidence is insufﬁcient for
a “recommendation” and provides support for “suggestions,”
for which care should be taken in application. Grade D
evidence is weak and does not provide support for “recom-
mendations” or “suggestions.” Expert consensus opinion was
used where grade C or above evidence was lacking.
Revision Dates
This guideline will be reviewed regularly, as mandated by
publication of substantive and high-quality medical
evidence that could potentially alter the original guideline
recommendations. If necessary, the entire panel will
reconvene to discuss potential changes. When appropriate,
panel members will recommend revision of the guideline to
their respective organizations for review and approval.
Conﬂict of Interest Policy
Before acceptance on the expert panel, potential member
authors from all guideline partnering organizations completed
the CAP conﬂict of interest process, whose policy and form
requires disclosure of material ﬁnancial interest in, or potential
for beneﬁt of signiﬁcant value from, the guideline’s develop-
ment or its recommendations beginning 12 months prior andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgending when the guideline was submitted for publication (see
Appendix). The potential members completed the conﬂict of
interest disclosure form conservatively, listing any relationship
that could be interpreted as constituting an actual, potential, or
apparent conﬂict. Regarding members declaring potentially
perceived or real conﬂict, guideline cochairs agreed that these
individuals would best serve as advisory panelmembers for the
guideline, but not authors on the expert panel.
Outcomes
CAP/IASLC/AMP Expert Panel Literature Review and
Analysis
The expert author panel cochairs (N.I.L., P.T.C., M.L.)
reviewed 1533 potentially relevant abstracts identiﬁed in the
original literature searches to select studies pertinent to the
guideline: 2 cochairs independently reviewed each abstract,
and disagreements were resolved by the third cochair. Full-
text articles (521) were then reviewed for all selected abstracts
by 2 members of the expert author panel; discrepancies were
resolved by a cochair. Evidence tables were developed from
selected studies that met the criteria for inclusion. A third
literature reviewwas performed by the authors of each section
of the guideline, to verify that the highest levels of evidence
supported each of their recommendations and, if not, to
reevaluate the recommendation and modify or defend it.
Consensus Development Based on Evidence
The entire panel met in December 2010 (Chicago, Illinois);
additional work on the guideline was completed through
electronic mail and monthly teleconferences of the cochairs
and/or expert panel. The purposes of the panel meeting were to
reﬁne the questions addressedby theguideline, solicit input and
testimony from the nonwriting advisory panel, and make
writing assignments for the respective sections.Allmembers of
the expert panel participated in the preparation of the draft
guideline,whichwas thendisseminated for reviewby the entire
panel. Feedback from external reviewers was also solicited.
The content of the guideline and themanuscript were reviewed
by an independent review panel and approved by the CAP
Transformation Program Ofﬁce Steering Committee, by the
IASLC Board of Directors, and by the AMP Clinical Practice
Committee and Executive Council. The recommendations are
summarized in Table 3.
Section I: When Should Molecular Testing for
NSCLC Be Performed?
Question 1: Which Patients Should Be Tested for EGFR
Mutations and ALK Rearrangements?
1.1a: Recommendation
EGFR molecular testing should be used to select patients
for EGFR-targeted TKI therapy, and patients with lung419
Table 3 Summary of Guideline Recommendations
Section I: When Should Molecular Testing of Lung Cancers Be Performed?
Question 1: Which Patients Should Be Tested for EGFR Mutations and ALK Rearrangements?
1.1a: Recommendation: EGFR molecular testing should be used to select patients for EGFR-targeted TKI therapy, and patients with lung
adenocarcinoma should not be excluded from testing on the basis of clinical characteristics.
1.1b: Recommendation: ALK molecular testing should be used to select patients for ALK-targeted TKI therapy, and patients with lung
adenocarcinoma should not be excluded from testing on the basis of clinical characteristics.
1.2: Recommendation: In the setting of lung cancer resection specimens, EGFR and ALK testing is recommended for adenocarcinomas
and mixed lung cancers with an adenocarcinoma component, regardless of histologic grade. In the setting of fully excised lung
cancer specimens, EGFR and ALK testing is not recommended in lung cancers that lack any adenocarcinoma component, such as
pure squamous cell carcinomas, pure small cell carcinomas, or large cell carcinomas lacking any immunohistochemistry (IHC)
evidence of adenocarcinoma differentiation.
1.3: Recommendation: In the setting of more limited lung cancer specimens (biopsies, cytology) where an adenocarcinoma component
cannot be completely excluded, EGFR and ALK testing may be performed in cases showing squamous or small cell histology but
clinical criteria (eg, young age, lack of smoking history) may be useful in selecting a subset of these samples for testing.
1.4: Recommendation: To determine EGFR and ALK status for initial treatment selection, primary tumors or metastatic lesions are
equally suitable for testing.
1.5: Expert consensus opinion: For patients with multiple, apparently separate, primary lung adenocarcinomas, each tumor may be
tested but testing of multiple different areas within a single tumor is not necessary.
Question 2: When Should a Patient Specimen Be Tested for EGFR Mutation or ALK Rearrangement?
2.1a: Recommendation: EGFR mutation testing should be ordered at the time of diagnosis for patients presenting with advanced-stage
disease (stage IV according to the 7th edition TNM staging system) who are suitable for therapy or at time of recurrence or
progression in patients who originally presented with lower-stage disease but were not previously tested.
2.1b: Suggestion: ALK rearrangement testing should be ordered at the time of diagnosis for patients presenting with advanced-stage
disease (stage IV according to the 7th edition TNM staging system) who are suitable for therapy or at time of recurrence or
progression in patients who originally presented with lower-stage disease but were not previously tested.
2.2a: Expert consensus opinion: EGFR testing of tumors at diagnosis from patients presenting with stage I, II, or III disease is
encouraged but the decision to do so should be made locally by each laboratory, in collaboration with its oncology team.
2.2b: Expert consensus opinion: ALK testing of tumors at diagnosis from patients presenting with stage I, II, or III disease is
encouraged, but the decision to do so should be made locally by each laboratory, in collaboration with its oncology team.
2.3: Recommendation: Tissue should be prioritized for EGFR and ALK testing.
Question 3: How Rapidly Should Test Results Be Available?
3.1: Expert consensus opinion: EGFR and ALK results should be available within 2 weeks (10 working days) of receiving the specimen
in the testing laboratory.
3.2: Expert consensus opinion: Laboratories with average turnaround times beyond 2 weeks need to make available a more rapid
test—either in-house or through a reference laboratory—in instances of clinical urgency.
3.3: Expert consensus opinion: Laboratory departments should establish processes to ensure that specimens that have a ﬁnal
histopathologic diagnosis are sent to outside molecular pathology laboratories within 3 working days of receiving requests and
to intramural molecular pathology laboratories within 24 hours.
Section II: How Should EGFR Testing Be Performed?
Question 4: How Should Specimens Be Processed for EGFR Mutation Testing?
4.1: Expert consensus opinion: Pathologists should use formalin-ﬁxed, parafﬁn-embedded (FFPE) specimens or fresh, frozen, or
alcohol-ﬁxed specimens for PCR-based EGFR mutation tests. Other tissue treatments (eg, acidic or heavy metal ﬁxatives, or
decalcifying solutions) should be avoided in specimens destined for EGFR testing.
4.2: Expert consensus opinion: Cytologic samples are also suitable for EGFR and ALK testing, with cell blocks being preferred over
smear preparations.
Question 5: What Are the Specimen Requirements for EGFR Testing?
5.1: Expert consensus opinion: Pathologists should determine the adequacy of specimens for EGFR testing by assessing cancer cell
content and DNA quantity and quality.
5.2: Expert consensus opinion: Each laboratory should establish the minimum proportion and number of cancer cells needed for
mutation detection during validation.
5.3: Expert consensus opinion: A pathologist should assess the tumor content of each specimen and either perform, or guide
a trained technologist to perform, microdissection for tumor cell enrichment as needed.
Question 6: How Should EGFR Testing Be Performed?
6.1: Recommendation: Laboratories may use any validated EGFR testing method with sufﬁcient performance characteristics.
6.2: Expert consensus opinion: Laboratories should use EGFR test methods that are able to detect mutations in specimens with at
least 50% cancer cell content, although laboratories are strongly encouraged to use (or have available at an external reference
laboratory) more sensitive tests that are able to detect mutations in specimens with as little as 10% cancer cells.
(table continues)
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Table 3 (continued)
6.3: Expert consensus opinion: Clinical EGFR mutation testing should be able to detect all individual mutations that have been
reported with a frequency of at least 1% of EGFR-mutated lung adenocarcinomas.
6.4: Recommendation: Immunohistochemistry for total EGFR is not recommended for selection of EGFR TKI therapy.
6.5: Recommendation: EGFR copy number analysis (ie, FISH or CISH) is not recommended for selection of EGFR TKI therapy.
Question 7: What Is the Role of KRAS Analysis in Selecting Patients for Targeted Therapy With EGFR TKIs?
7.1: Recommendation: KRAS mutation testing is not recommended as a sole determinant of EGFR TKI therapy.
Question 8: What Additional Testing Considerations Are Important in the Setting of Secondary or Acquired EGFR TKI Resistance?
8.1: Recommendation: If a laboratory performs testing on specimens from patients with acquired resistance to EGFR kinase
inhibitors, such tests should be able to detect the secondary EGFR T790M mutation in as few as 5% of cells.
Section III: How Should ALK Testing Be Performed?
Question 9: What methods should be used for ALK testing?
9.1: Recommendation: Laboratories should use an ALK FISH assay using dual-labeled break-apart probes for selecting patients for ALK
TKI therapy; ALK immunohistochemistry, if carefully validated, may be considered as a screening methodology to select
specimens for ALK FISH testing.
9.2: Recommendation: RT-PCR is not recommended as an alternative to FISH for selecting patients for ALK inhibitor therapy.
9.3: Expert consensus opinion: A pathologist should be involved in the selection of sections for ALK FISH testing, by assessing tumor
architecture, cytology, and specimen quality.
9.4: Expert consensus opinion: A pathologist should participate in the interpretation of ALK FISH slides, either by performing the analysis
directly or by reviewing the interpretations of cytogeneticists or technologists with specialized training in solid tumor FISH analysis.
9.5: Expert consensus opinion: Testing for secondary mutations in ALK associated with acquired resistance to ALK inhibitors is not
currently required for clinical management.
Section IV: Should Other Genes Be Routinely Tested in Lung Adenocarcinoma?
Question 10: Are Other Molecular Markers Suitable for Testing in Lung Cancer?
10.1a: Recommendation: Testing for EGFR should be prioritized over other molecular markers in lung adenocarcinoma.
10.1b: Suggestion: After EGFR testing, testing for ALK should be prioritized over other proposed molecular markers in lung
adenocarcinoma, for which published evidence is insufﬁcient to support testing guideline development at the present time.
Section V: How Should Molecular Testing of Lung Adenocarcinomas Be Implemented and Operationalized?
Question 11: Must All Adenocarcinomas Be Tested for Both EGFR and ALK?
11.1: Expert consensus opinion: Laboratories may implement testing algorithms to enhance the efﬁciency of molecular testing of lung
adenocarcinomas, provided the overall turnaround time requirements are met.
Question 12: How Should EGFR and ALK Results Be Reported?
12.1: Expert consensus opinion: EGFR mutation testing reports and ALK FISH reports should include a results and interpretation
section readily understandable by oncologists and by nonspecialist pathologists.
Question 13: How Should EGFR and ALK Testing Be Validated?
13.1: Expert consensus opinion: EGFR and ALK testing validation should follow the same guidelines as for other molecular diagnostics
and FISH tests.
Question 14: How Should Quality Assurance Be Maintained?
14.1: Expert consensus opinion: Laboratories should follow similar quality control and quality assurance policies and procedures for
EGFR and ALK testing in lung cancers as for other clinical laboratory assays. In particular, laboratories performing EGFR and ALK
testing for TKI therapy should enroll in proﬁciency testing, if available.
CISH, chromogenic in situ hybridization; EGFR, epidermal growth factor receptor; FISH, ﬂuorescence in situ hybridization; PCR, polymerase chain reaction;
RT-PCR, reverse transcription–polymerase chain reaction; TKI, tyrosine kinase inhibitor; TNM, tumor, node, metastasis.
Lung Cancer Molecular Testing Guidelinesadenocarcinoma should not be excluded from testing on the
basis of clinical characteristics.
1.1b: Recommendation
ALK molecular testing should be used to select patients for
ALK-targeted TKI therapy, and patients with lung adeno-
carcinoma should not be excluded from testing on the basis
of clinical characteristics.
Evidence Grade. EGFR: A; ALK: B: Clinical characteristics
(eg, age, sex, ethnicity, smoking history) are not sufﬁ-
ciently sensitive or speciﬁc to be used to select or exclude
patients for treatment or testing. Ethnicity, smoking history,The Journal of Molecular Diagnostics - jmd.amjpathol.organd sex have all been associated with the presence of EGFR
mutations in NSCLC. Multiple studies have established that
EGFR mutations are more common in women than men, in
patients who have never smoked tobacco than in patients who
have smoked tobacco, and in East Asians than in other ethnic
groups.7,25e29 In contrast to EGFR-mutated lung cancer, ALK
gene fusions do not show sharp differences in prevalence
according to sex and ethnic origin, but do show a similar
strong association with patients who have never smoked
tobacco and younger age.11,18,30,31 However, while these
clinical characteristics may have value for population studies,
they are insufﬁciently speciﬁc to be used to select individual
patients for treatment with a targeted inhibitor. Similarly,421
Table 4 EGFR Mutation Prevalence in Different Lung Adenocar-
cinoma Patient Populations
EGFR
mutation
prevalence, %
EGFR
mutation
positive
EGFR
mutation
negative n (N)
Asian/Paciﬁc* 45 1547 1905 31 (3452)
Whitey 24 853 2681 10 (3534)
African Americanz 20 19 78 3 (97)
Hispanicx 17 65 307 4 (372)
Asian/Indian{ 52 114 106 1 (220)
Data for other populations were absent or too limited for analysis.
*References 7, 17, 32, 35, 48, 49, 55, 133, 184, 185, 191, 257, 264,
269, 270, 272e276, 278, 283e292.
yReferences 17, 32, 191, 192, 253, 273, 288, 292e294.
zReferences 256, 288, 293.
xReferences 128, 254, 267, 288.
{Reference 295.
n, number of studies; N, number of patients.
Table 5 Clinicopathologic Characteristics in Relation to EGFR
Mutation Status in Studies Containing Primarily Asian Patients
EGFR
mutation
prevalence,
%
EGFR
mutation
positive
EGFR
mutation
negative n (N)
Age with cutoff, years
<65* 46 370 433 6 (803)
65y 38 432 709 5 (1141)
Sex
Femalez 58 1027 733 27 (1760)
Malex 32 456 962 26 (1418)
Smoking
Never{ 58 843 599 22 (1442)
Ever{ 26 265 767 22 (1032)
History of smoking, pack-years
0e10k 67 10 5 1 (15)
11e40k 45 5 6 1 (11)
>40k 23 5 17 1 (22)
>20** 25 13 40 1 (53)
Histology
Adenocarcinomayy 50 1278 1256 25 (2534)
Squamouszz 5 8 160 8 (168)
Adenosquamousxx 67 4 2 2 (6)
Large cell{{ 7 1 14 4 (15)
Differentiation
Two grades
Wellkk 37 62 107 3 (169)
Moderate
to poorkk
14 27 162 3 (189)
Three grades***
Well 65 28 15 2 (43)
Moderate 48 59 63 2 (122)
Poor 34 17 33 2 (50)
Most studies contained primarily patients with adenocarcinoma.
*References 7, 55, 184, 272, 276, 290.
yReferences 55, 184, 272, 276, 290.
zReferences 7, 32, 35, 48, 49, 55, 133, 184, 185, 257, 264, 269, 270,
272, 274e276, 278, 283e287, 289e291, 296.
xReferences 32, 35, 48, 49, 55, 133, 184, 185, 257, 264, 269, 270, 272,
274e276, 278, 283e287, 289e291, 296.
{References 32, 35, 55, 133, 184, 185, 257, 264, 269, 270, 274e276,
278, 283e285, 287, 289e291, 296.
kReference 290.
**Reference 272.
yyReferences 32, 35, 48, 49, 55, 133, 184, 185, 257, 264, 269, 270, 272,
274e276, 278, 283e286, 289e291, 296.
zzReferences 55, 257, 264, 272, 274, 275, 289, 296.
xxReferences 272, 289.
{{References 48, 272, 275, 289.
kkReferences 119, 184, 202.
***References 49, 184.
n, number of studies; N, number of patients.
Lindeman et althese characteristics are insufﬁciently sensitive to be used as
prerequisites for testing an individual patient for EGFR
mutation or ALK fusion, as signiﬁcant numbers of patients
who might beneﬁt from EGFR- or ALK-targeted therapy
might be inappropriately excluded (Tables 4, 5, 6, and 7).
Prediction models combining several of these variables to
deﬁne patients who have a very low probability of EGFR
mutations (eg, <1%) have been developed but will require
further evaluation.32,33
1.2: Recommendation
In the setting of lung cancer resection specimens, EGFR and
ALK testing is recommended for adenocarcinomas andmixed
lung cancers with an adenocarcinoma component, regardless
of histological grade. In the setting of fully excised lung
cancer specimens, EGFR and ALK testing is not recom-
mended in lung cancers that lack any adenocarcinoma
component, such as “pure” squamous cell carcinomas, “pure”
small cell carcinomas, or large cell carcinomas lacking any
immunohistochemistry (IHC) evidence of adenocarcinoma
differentiation.
Evidence Grade. EGFR and ALK: A: As a preamble to the
discussion of this recommendation, we note that “nonesmall
cell” lung carcinoma is no longer considered appropriate as
a pathological diagnosis for resection specimens or as an oper-
ational category for clinical management. This evolution is also
reﬂected in the version 3.2012 NCCN guidelines that recom-
mend avoiding use of the generic term nonesmall cell lung
carcinoma (NSCLC) as a single diagnostic term for complete
resection specimens.34 The distinction between squamous
carcinoma, small cell carcinoma, neuroendocrine carcinoma,
and adenocarcinomas has become critical for determining
subsequent molecular characterization of tumors and patient
management.
EGFRmutations have been detected in several histological
lung cancer types, but most tumors with EGFRmutations are422adenocarcinomas or mixed carcinomas with an adenocarci-
noma component, including adenosquamous carcinomas.
While there is some evidence that EGFR mutations are more
likely in low-grade adenocarcinomas with lepidic, papillary,
or acinar histology than in poorly differentiated, mucinous,
or solid adenocarcinomas, EGFR mutations are found atjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 6 Clinicopathologic Characteristics in Relation to EGFR
Mutation Status in Studies Containing Primarily Non-Asian Patients
EGFR
mutation
prevalence,
%
EGFR
mutation
positive
EGFR
mutation
negative n (N)
Sex
Female* 28 859 2239 19 (3098)
Male* 18 397 1768 19 (2165)
Smoking
Nevery 45 666 805 18 (1471)
Every 15 569 3154 18 (3723)
History of smoking,
pack-years
0e10z 39 18 28 1 (46)
11e50z 8 7 86 1 (93)
>50x 5 3 56 1 (59)
Histology
Adenocarcinomax 24 1266 3918 19 (5184)
Squamous{ 5 6 104 9 (110)
Adenosquamousk 13 1 7 2 (8)
Large cell** 5 2 37 6 (39)
Most studies contained primarily patients with adenocarcinoma.
*References 17, 32, 87, 115, 128, 191e193, 253, 254, 256, 267, 273,
288, 292e295, 297.
yReferences 17, 32, 87, 128, 191e193, 253, 254, 256, 267, 273, 288,
292e295, 297.
zReference 288.
xReferences 17, 32, 87, 115, 128, 191e193, 253, 254, 256, 267, 273,
288, 292e294, 297, 298.
{References 17, 191, 193, 254, 256, 267, 273, 288, 298.
kReferences 17, 288.
**References 17, 193, 254, 267, 273, 298.
n, number of studies; N, number of patients.
Lung Cancer Molecular Testing Guidelinessigniﬁcant frequencies in adenocarcinomas of all grades.
Therefore, adenocarcinoma subtype should not be used as
a determinant of which samples should, or should not, be
tested.35e38
ALK rearrangements are also associated with adenocar-
cinoma histology, without any single subtype being
strongly predictive. Studies in Western populations have
shown that ALK rearrangements are more frequent in
adenocarcinomas with largely solid histology and/or signet
ring cells, but this has not been observed in East Asian
populations.17,39,40 ALK fusions appear very infrequent in
squamous cell carcinomas lacking any adenocarcinoma
component (Table 8) but have been reported in adenos-
quamous carcinomas.41
Likewise, EGFR mutations are very infrequent in well-
characterized fully excised specimens of squamous cell
carcinoma lacking any adenocarcinoma component.35,38,42e51
A few studies52e60 have reported EGFR mutations in squa-
mous cell carcinoma at a low frequency (Table 9). Most of
these latter studies have focused on molecular or clinical data
from patients with advanced disease diagnosed by small
biopsies, raising concerns that many, if not most, of these
EGFR-mutated “squamous” cancers may have been smallThe Journal of Molecular Diagnostics - jmd.amjpathol.orgbiopsies in which the diagnosis of adenosquamous or
poorly differentiated adenocarcinomas can be chal-
lenging.35,40 As this histological distinction is becoming
critical in the selection of cases for mutation analysis, in
cases where the distinction between poorly differentiated
squamous cell carcinoma and poorly differentiated adeno-
carcinoma is especially difﬁcult, appropriate IHC should be
performed for TTF-1, p63, or p40, and other relevant
markers.61e63 Likewise, undifferentiated or large cell
carcinomas with histochemical or immunohistochemical
evidence of adenocarcinoma lineage (eg, TTF-1 or mucin
positive) or lacking IHC evidence of squamous carcinoma
lineage (eg, p63 or p40 negative) are also appropriate for
EGFR and ALK testing. The use of IHC and other special-
ized histochemical techniques to establish lineage in lung
adenocarcinoma is an evolving ﬁeld (and the selection of
stains/antibodies and their associated interpretive criteria)
and is outside the scope of this guideline. The interested
reader is referred to published IASLC guidelines for an
introduction to this topic.63
EGFR mutations have not been detected in small cell lung
cancer (SCLC), except in rare cases of combined SCLC
with an adenocarcinoma component; in some of these cases
a response to EGFR TKI was reported.64e69 In addition,
adenocarcinomas with EGFR mutations may show trans-
formation to small cell histology at relapse, as a mechanism
of resistance in these patients, the recurrence of the lung
cancer as a small cell carcinoma retains the EGFR mutation
that were initially treated successfully with an EGFR TKI
from the antecedent adenocarcinoma.69e71
Among other subtypes of lung cancer, rare EGFR muta-
tions have been reported in pulmonary salivary glandetype
tumors, large cell carcinomas, sarcomatoid carcinomas, and
large cell neuroendocrine carcinoma.34,72e77 This guideline
does not make speciﬁc recommendations for these less
common tumors, although testing of large cell carcinomas
showing IHC evidence of adenocarcinoma differentiation
should be considered.77 EGFR mutations have not been
found in carcinoids.78
1.3: Recommendation
In the setting of more limited lung cancer specimens
(biopsies, cytology) where an adenocarcinoma component
cannot be completely excluded, EGFR and ALK testing may
be performed in cases showing squamous or small cell
histology but clinical criteria (eg, young age, lack of
smoking history) may be useful in selecting a subset of these
samples for testing.
Evidence Grade. EGFR andALK: A: Lung cancers with mixed
histology (eg, adenosquamous, mixed adeno/small cell) can
have mutations in EGFR or rearrangements in ALK and, if so,
respond to treatment.79 Therefore, in tissues with incomplete
sampling in which the possibility of an adenocarcinoma
component cannot be excluded, testing may be indicated.
In this context, clinical criteria, such as young age, lack of423
Table 7 Clinicopathologic Characteristics in Relation to ALK Rearrangement Status
ALK rearrangement
prevalence, %
ALK rearrangement
positive
ALK rearrangement
negative n (N)
Age with cutoff, years
6520 6 13 210 1 (223)
>6520 3 6 224 1 (230)
Sex
Females11,12,15,20 5 28 579 4 (607)
Males11,12,15,20 4 30 738 4 (768)
Smoking
Never11,15,20 8 30 331 3 (361)
Ever11,15,20 3 20 652 3 (672)
Ethnicity
Asian/Paciﬁc11,12,14 5 35 654 3 (689)
White12,15 4 22 474 2 (496)
Histology
Adenocarcinoma9,11,12,15,16,19,20 5 67 1319 7 (1386)
Squamous9,11,12,16,19,20 0.2 1 522 6 (523)
Adenosquamous11,12,19 0 0 19 3 (19)
Differentiation
Well11 1 1 97 1 (98)
Not well11 6 10 145 1 (155)
Most studies contained primarily patients with adenocarcinoma.
n, number of studies; N, number of patients.
Lindeman et alsmoking history, or a documented preceding adenocarcinoma,
may be used to select patients for testing.
1.4: Recommendation
To determine EGFR and ALK status for initial treatment
selection, primary tumors or metastatic lesions are equally
suitable for testing.
Evidence Grade. EGFR and ALK: B: Discordances in EGFR
mutation status between primary tumors and corresponding
metastases appear rare80 (Table 10). The clinical signiﬁcance
of these relatively uncommon discrepancies remains
uncertain but it should be noted that some discrepancies may
reﬂect the higher risk of false negatives when analyzing lung
cancer metastatic to lymph nodes due to the admixture of
lymphoid cells. Accordingly, the choice of which sample to
test should be based primarily on the specimen qualities
themselves (tumor content and preservation), rather than
whether they are primary or metastatic lesions. All things
being equal, the most recent available tissue is preferred, but
no evidence supports subjecting a patient to a procedure to
procure tissue speciﬁcally to obtain testing of a metastasis
before initiation of TKI therapy when an earlier primaryTable 8 Studies Speciﬁcally Reporting Outcome of ALK Rear-
rangement Studies in Squamous Cell Carcinomas
Source, year n
ALK rearrangement
positive, %
Takeuchi et al,299 2008 71 0
Takahashi et al,39 2010 75 0
Inamura et al,10 2008 48 0
n, number of squamous cell carcinoma samples tested.
424lesion is available and suitable for analysis, unless there is
a strong clinical suspicion of its origin from a separate
primary tumor.
This is in contrast to patients with metastasis or relapse
after initially successful response to TKI treatment (ie,
acquired resistance), in which case repeated biopsies are
performed to conﬁrm a clonal relationship to the treated
primary tumor, permit analysis of the mechanism of resis-
tance and, potentially, direct the patient to targeted, protocol-
based experimental therapies that may differ according to the
mechanism of acquired resistance.
1.5: Expert Consensus Opinion
For patients with multiple, apparently separate, primary lung
adenocarcinomas, each tumor may be tested but testing of
multiple different areas within a single tumor is not
necessary.
Separate primary tumors that harbor different mutations are
not uncommon.81 If an EGFR mutation is discovered in any
tumor, the patient may beneﬁt from an EGFRTKI. Therefore, if
a patient presents with apparently separate primary tumors
(based on location and nonoverlapping histological features),
each primary tumor may be tested. However, the decision
whether or not to test eachof a patient’smultiple tumors depends
on each patient’s clinical context and requires communication
between the laboratory and the clinical care team.
Adequate evidence has not been published to support
mutation analysis of different regions of a tumor, neither with
respect to mutation sensitivity in otherwise sufﬁciently
cellular regions, nor with respect to clinical outcomes.
Although some data suggest that variation in EGFR copy
number within a tumor may impact mutation detection rate injmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 9 Major Studies Speciﬁcally Reporting EGFR Mutation Analysis in Surgically Resected Squamous Cell Carcinomas as Compared to
Adenocarcinomas
Source, year
Predominant ethnic
origin of study population
EGFR mutations in resected
adenocarcinomas, No. (%)
EGFR mutations in resected
squamous cell carcinomas, No. (%)
Marchetti et al,45 2005 European 39/375 (10.4) 0/454
Sugio et al,43 2006 Asian 136/322 (42.2) 0/102
Tsao et al,44 2006 North American 14/96 (14.6) 0/63
Tsao et al,60 2011 North American 32/231 (13.9) 8/162 (4.9)
Bae et al,284 2007 Asian 20/55 (36.4) 0/60
Lee et al,300 2010 Asian 36/117 (30.8) 0/56
Miyamae et al,301 2011 Asian . 3/87* (3.4)
Rekhtman et al,36 2012 North American . 0/95
TCGA,302,* 2012 North American . 2/178y (1.1)
These numbers do not include 2 EGFR-mutated cases reclassiﬁed as adenocarcinoma and adenosquamous carcinoma on the basis of immunohistochemistry
(IHC) for thyroid transcription factor 1 (TTF-1)/p63; the remaining 3 EGFR-mutated cases were reported as IHC-conﬁrmed squamous cell carcinoma.
*The Cancer Genome Atlas Research Network.
yBoth EGFR mutations were L861R.
Lung Cancer Molecular Testing Guidelinessamples from different zones of the tumor, performing FISH
to select an area for mutation testing is impractical, and any
area with sufﬁcient tumor content to enable detection of
a mutation may be selected for analysis.80,82e84 Recent
detailed genomic studies in other cancers have provided
further support for the concept that key driver mutations are
well preserved but secondary mutations are not.85 As key
driver mutations, EGFRmutations and ALK fusions appear to
follow this pattern and this is further supported by the
extreme rarity of the EGFR wild-type recurrent tumors in
patients with EGFR-mutated lung adenocarcinomas treated
with EGFR TKIs.70Question 2: When Should a Patient Specimen Be Tested
for EGFR Mutation or ALK Rearrangement?
2.1a: Recommendation
EGFR mutation testing should be ordered at the time of
diagnosis for patients presenting with advanced-stage
disease (stage IV according to the seventh edition tumor
node metastasis [TNM] staging system) who are suitable for
therapy, or at time of recurrence or progression in patients
who originally presented with lower-stage disease but were
not previously tested.
2.1b: Suggestion
ALK rearrangement testing should be ordered at the time of
diagnosis for patients presenting with advanced-stage disease
(stage IV according to the seventh edition TNM stagingTable 10 Summary of Studies of the Concordance of EGFR
Mutations in Primary Versus Metastatic Tumors in the Same Patient
Metastatic lesions
Primary tumor
EGFRþ EGFR
EGFRþ 108 6
EGFR 11 183
Data derived from Park et al57; Yatabe et al80; and Sun et al.303
The Journal of Molecular Diagnostics - jmd.amjpathol.orgsystem) who are suitable for therapy, or at time of recurrence
or progression in patients who originally presented with
lower-stage disease but were not previously tested.
Evidence Grade. EGFR: A; ALK: C: Patients with advanced-
stage disease have short life expectancies, on the order of 4
to 5 months in the absence of treatment. Although patients
may derive some beneﬁt from ﬁrst-line chemotherapy
with use of targeted TKIs as second-line agents, patients
with EGFR mutations/ALK rearrangements show superior
outcomes when the targeted TKI therapies are administered
as ﬁrst-line agents.34,86 For these patients, timely diagnosis
is critical and molecular testing should be initiated as soon
as a diagnosis of adenocarcinoma is established.
Reﬂex testing, a testing policy that does not require
a separate clinician order for each case, is appropriate if
agreed on by the lung cancer care team and may help to
ensure expedited and consistent routing of specimens for
molecular testing. However, some patients may not be
candidates for targeted TKI therapy for clinical reasons, and
good communication between the clinical care team and the
testing laboratory is needed to ensure testing is performed for
patients whose management will be impacted by the test
result. Speciﬁcally, testing is not necessary for patients with
stage IV disease who are being considered for palliative or
hospice care only. Similarly, in settings in which reﬂex
testing is the practice, a mechanism should be provided for
the clinical care team to communicate to the pathologist
examining a small biopsy or cytology sample when a more
suitable diagnostic specimen (eg, a resection) is expected to
be obtained, and the molecular testing should be deferred to
the subsequent, more generous sample.
2.2a: Expert Consensus Opinion
EGFR testing of tumors at diagnosis from patients pre-
senting with stage I, II, or III disease is encouraged but the
decision to do so should be made locally by each laboratory,
in collaboration with its oncology team.425
Lindeman et al2.2b: Expert Consensus Opinion
ALK testing of tumors at diagnosis from patients presenting
with stage I, II, or III disease is encouraged, but the decision
to do so should be made locally by each laboratory, in
collaboration with its oncology team.
Patients with localized disease have a potential for surgical
cure and may never need targeted therapies. Testing the initial
surgical specimen at the time of resection affords the beneﬁts of
having recent tissue to test as well as, in many instances, larger
resection specimens with ample material. By contrast,
excluding patients with early-stage disease from testing and
waiting until progression may necessitate testing of a smaller
biopsy sample of borderline quality or quantity and/or sub-
jecting patients to invasive procedures to obtain adequate
samples, or trying to retrieve the earlier resection specimen from
long-term storage or from another institution, which can be
challenging and time-consuming. Furthermore, EGFR testing
may have use as a favorable prognostic factor, beyond its use as
a predictor of response to targeted inhibitors.86,87
These beneﬁts of testing all early-stage disease patientsmust
be balanced against the cost of performing testing that may not
be used to select therapy for the patientswho never relapse. The
portability of the initial testing results should also be consid-
ered, in the case of a patient with a delayed relapse who may
present for targeted therapy years later at another institution.
Currently, the question of whether or not to test a diagnostic
specimen in early-stage disease is a local decision that must be
made in conjunctionwith each institution’s oncologycare team,
as insufﬁcient published evidence supports a universal recom-
mendation. However, evidence to support this treatment prac-
tice may be forthcoming. Traditionally, most novel therapeutic
agents are studied initially in patientswith advanceddisease that
is refractory to standard therapy. If activity is noted in this
setting, the agents are typically next studied in the ﬁrst-line
setting for advanced-stage disease. If activity is noted in this
setting, then the agent may be studied in earlier-stage disease.
This is where EGFR inhibitors are todaydgiven the success in
ﬁrst-line treatment of patients with advanced-stage disease and
EGFRmutations, a next wave of clinical trials will test whether
these agents may be beneﬁcial as adjuvant therapy in early-
stage disease, a notion already supported by retrospective
analyses.88ALKtherapy is one step removed, as trials testing its
value as ﬁrst-line therapy in advanced disease are ongoing.
2.3: Recommendation
Tissue should be prioritized for EGFR and ALK testing.
Evidence Grade. EGFR:A;ALK: B: EGFR andALK testing are
the most important uses of the diagnostic sample after a diag-
nosis of adenocarcinoma is established. If specimens are insuf-
ﬁcient for molecular testing, patients may need to undergo
another invasivediagnostic procedurebefore they canbe treated.
Therefore, it is critical to retain sufﬁcient material for molecular
analysis and tobe judicious in theuseof sections for IHCstudies,
histochemical stains, or deeper levels thatmay not be essential to
establish a histopathological diagnosis. This is particularly426critical for specimens that have a limited amount of cancer cells.
This concept has also now been incorporated into the new
IASLC classiﬁcation.63 In instances where there is not enough
tissue for EGFR and ALK testing, pathologists should alert the
oncologist and include a note in the surgical pathology report
to this effect. Because substantial tissue can be lost when
blocks are refaced in histology laboratories while cutting
unstained slides after initial sectioning, consideration should
be given to cutting multiple additional unstained sections “up
front” when the sample is ﬁrst processed in histology. These
unstained sections could then be used for deeper levels or
additional histochemical/immunohistochemical stains as
needed to establish the diagnosis, and for ensuing molecular
testing, without having to reface and recut the blocks. The
beneﬁt of such a sample-sparing protocol must be balanced
against the cost of cutting additional sections, some of which
might not be used.
Question 3: How Rapidly Should Test Results Be
Available?
3.1: Expert Consensus Opinion
EGFR and ALK results should be available within 2 weeks
(10 working days) of receiving the specimen in the testing
laboratory.
Clinical response to EGFR TKI in EGFR-mutated tumors is
typically seen rapidly, and the drugs themselves have relatively
modest side effects when compared to platinum-based
chemotherapy.89 For these reasons, some oncologists are
willing to initiate EGFR TKI therapy before the EGFR test
result is available. However, randomized controlled trials have
demonstrated that EGFR wild-type tumors respond better to
conventional chemotherapy than to EGFRTKIs.7,26,90,91 Thus,
in most clinical circumstances, EGFR TKI therapy should not
be administered as ﬁrst-line therapy without evidence of
a sensitizing EGFR mutation. Therefore, the turnaround time
(TAT) for EGFR testing has become increasingly important,
especially for patients with advanced-stage disease.
To that end, and in the absence of published data establishing
an evidence-based recommendation, it is our expert consensus
opinion that a TAT goal of 1 week (5 working days) should be
established for EGFR and ALK testing, up to a maximum TAT
of 2 weeks (10 working days). This TAT refers to the period
from the receipt of suitablematerial by themolecular pathology
laboratorywhere the testing is performed to the reporting of the
ﬁnal results to the clinical care team, and is not related to the
period of time between when a patient undergoes a diagnostic
procedure and when a specimen is submitted to the laboratory
for testing. We consider achieving this TAT goal to be most
critical for patients with advanced-stage disease, although we
believe it is a reasonable goal for all testing.
3.2: Expert Consensus Opinion
Laboratories with average TATs beyond 2 weeks need to
make available a more rapid testdeither in-house or through
a reference laboratorydin instances of clinical urgency.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Lung Cancer Molecular Testing GuidelinesPatients with stage IV lung cancer have median untreated
life expectancy of approximately 16 weeks; 20% of this time
should not be spent waiting for test results. If laboratories
cannot provide results for the sickest of patients within 2
weeks, then they need to make available a method or another
laboratory that can. This is particularly germane for large-
scale multiplexed assays that afford the capability of testing
many genes at once but may take several weeks to complete
and analyze. While this technology has great scientiﬁc
promise and platform consolidation is logistically appealing,
the ability to generate large amounts of data of unproven
signiﬁcance should not take precedence over the timely
generation of clinically useful data. This recommendation is
based on expert consensus, given the lack of published
experimental data addressing this topic.
3.3: Expert Consensus Opinion
Laboratory departments should establish processes to ensure
that specimens that have a ﬁnal histopathological diagnosis
are sent to outside molecular pathology laboratories within 3
working days of receiving requests and to intramural
molecular pathology laboratories within 24 hours.
Another critical component of the overall testing time is
the delivery of tissues necessary to perform these tests, both
between institutions and within pathology departments. It is
our expert consensus opinion that pathology departments
should have established processes in place to retrieve and
send out materials (blocks or unstained sections) within 3
working days of receiving such requests, once a ﬁnal
histopathological diagnosis has been established. In local
cases, where tumor material must be transferred from
surgical pathology or cytology to the molecular diagnostic
laboratory, intradepartmental delivery of materials should
occur within 1 working day for ﬁnalized current or recent
(eg, not in long-term storage) cases. As stated above, reﬂex
testing and/or preparation of unstained recut sections at the
time the sample is ﬁrst processed in the histology laboratory
may help to ensure expedited and consistent intra-
departmental routing of specimens for molecular testing.
Molecular pathology laboratories with high demand for
these tests in otherwise busy pathology departments may
beneﬁt fromhaving a specialized histological service dedicated
to expeditious processing of samples for molecular testing
within the pathology department or having a dedicated
histology technician and equipment within the molecular
pathology laboratory.
Section II: How Should EGFR Testing Be
Performed?
Question 4: How Should Specimens Be Processed for
EGFR Mutation Testing?
4.1: Expert Consensus Opinion
Pathologists should use formalin-ﬁxed, parafﬁn-embedded
(FFPE) specimens or fresh, frozen, or alcohol-ﬁxedThe Journal of Molecular Diagnostics - jmd.amjpathol.orgspecimens for polymerase chain reaction (PCR)ebased
EGFR mutation tests. Other tissue treatments (eg, acidic or
heavy metal ﬁxatives, or decalcifying solutions) should be
avoided in specimens destined for EGFR testing.
The effects of ﬁxation and preanalytic specimen pro-
cessing are no different for EGFR mutation analysis than for
other molecular diagnostics applications that rely on PCR
ampliﬁcation, and EGFR testing can be performed on fresh,
frozen, FFPE, or alcohol-ﬁxed specimens. Accordingly,
molecular tests should be validated for each of the specimen
types likely to be encountered (ie, FFPE, fresh, frozen,
alcohol ﬁxed), and testing should be performed and reported
only on validated specimen types. Other specimen types
should be rejected as inadequate or tested at the discretion of
the laboratory director, with clear communication that the
test was performed on a nonvalidated specimen type.
Fresh or frozen specimens are optimal for analysis of long
(ie, >1000 bp) DNA segments.92e94 However, this is not
typically necessary for EGFR testing. One drawback to
testing fresh or frozen tissues is the need for correlative
histological examination, which may require cutting and
staining frozen sections ﬂanking the portion of the specimen
submitted for testing. In contrast, the use of FFPE material
for DNA extraction allows a more convenient and accurate
assessment of tumor content.
Different tissue ﬁxatives, processing protocols, and
storage conditions, with associated variations in chemical
and physical conditions, including time to ﬁxation, mecha-
nism of ﬁxation, processing temperature, pressure, and pH,
storage time and conditions, all can affect the quality and
quantity of DNA, RNA, and proteins in the specimens,
and their analyses. Selection of a proper section for analysis,
and correct interpretation of negative results, requires that
the molecular pathology laboratory have access to this
information.
Ten percent neutral-buffered formalin is the ﬁxative that
is most widely used, and most molecular assays have been
optimized and validated on such tissues. Formalin ﬁxation
leads to chemical cross-links to proteins, RNA, and other
DNA molecules, with concomitant fragmentation of DNA,
which inhibits molecular analysis in a length-dependent
fashion. In general, molecular analyses of formalin-ﬁxed
DNA that require DNA segments shorter than 300 bp are
usually successful, while those requiring a length between
300 and 1000 bp succeed inconsistently, and those requiring
a length of greater than 1000 bp are often unsuccessful.92
Formalin ﬁxation also causes random nucleotide base
changes, which can lead to false-positive results, typically in
samples with low DNA concentration or with ultrasensitive
assays.95e97
Alcohol (70% ethanol) has been shown to be comparable
to, if not better than, 10% neutral-buffered formalin for
molecular assays requiring nucleic acid extraction, but
alcohol is not a favored ﬁxative in routine histology labo-
ratories for a variety of reasons, including tradition, safety,
cost, and compatibility with some other FDA-approved427
Lindeman et alprocedures (eg, ERBB2 [HER2/neu] FISH, estrogen receptor
IHC).93,98 Most cytology ﬁxatives are alcohol based and,
therefore, cytology specimens are typically suitable for
DNA-based molecular assays.99e101
Most molecular analyses are inhibited by heavy metal
ﬁxatives (eg, Zenker, B5, B plus, acid zinc formalin) owing
to competition between the metals in the ﬁxative and the
magnesium needed as a cofactor for most DNA polymerases
and other enzymes involved in molecular methods.93,102,103
Specimens processed with heavy metal ﬁxatives should not
be used for EGFR testing.
Acidic solutions (eg, Bouin solution, bone-decalcifying
solutions) fragment DNA extensively.104,105 Tissues treated
with acidic solutions should not be used for EGFR testing.
This is particularly problematic for analysis of bone
metastases, which are usually decalciﬁed in acidic solutions.
The use of nonacidic chelating decalcifying solutions may
better preserve DNA for molecular testing.105 Moreover,
unbuffered formalin spontaneously oxidizes to formic acid
over time.106
The relatively broad time range of specimen ﬁxation found
in pathology practice usually has no effect on morphological
details, but longer durations of ﬁxation adversely affect the
quality of nucleic acid.92 Fixation times of 6 to 12 hours for
small biopsy samples and 8 to 18 hours for larger surgical
specimens generally give best results, although our expert
consensus opinion is that ﬁxation times of 6 to 48 hours
should give acceptable results, in accordance with CAP
Laboratory Accreditation Program Checklist MOL.39358 for
HER2/neu in situ hybridization.98,107 This is a generalization,
however, and the effect of extreme ﬁxation times should be
assessed by each laboratory during validation. This knowl-
edge should be incorporated into the interpretation and
reporting of molecular pathology results when ﬁxation times
are extreme.
4.2: Expert Consensus Opinion
Cytologic samples are also suitable for EGFR and ALK
testing, with cell blocks being preferred over smear
preparations.
Although it has been shown that smears can be used
effectively for DNA extraction for EGFR mutation assays, it
is our expert consensus opinion that, for cytology specimens
such as malignant pleural effusions, use of a cell block is
recommended over smear preparations because of the ability
to correlate with malignant cell content, the preservation of
the original diagnostic specimen, and the possible retention of
morematerial for additional diagnostic studies.62,101,108,109 In
addition, analysis of FISH requires nonoverlapping tumor
cells, which can be a challenge to identify on 40,6-diamidino-
2-phenyl-indole (DAPI)estained smears. As with surgical
pathology specimens, the cell pellet should be ﬁxed in 10%
neutral-buffered formalin for 6 to 48 hours before processing.
Fixation in 70% ethanol is also acceptable; in which case
validation of the molecular assays on DNA extracted from
alcohol-ﬁxed tissues should be done.428Question 5: What Are the Specimen Requirements for
EGFR Testing?
5.1: Expert Consensus Opinion
Pathologists should determine the adequacy of specimens
for EGFR testing by assessing cancer cell content and DNA
quantity and quality.
EGFR mutation testing can be performed on specimens
procured by almost any procedure: surgical resection, open
biopsy, endoscopy, transthoracic needle biopsy, ﬁne-needle
aspiration, or thoracentesis. In general, larger tumor speci-
mens (eg, resections) are generally preferred for mutation
assays because of greater amount of material and greater
capacity to enrich the malignant content by dissection.
However, most advanced-stage lung tumor specimens are
small biopsy or cytology specimens such as pleural ﬂuids or
ﬁne-needle aspirates. EGFR mutation assays have been
shown to be able to detect mutations from cytologic speci-
mens, particularly if cell blocks are available.109e114 Ulti-
mately, any specimen that meets the laboratory’s
requirements for tumor content, ﬁxation, and quality, as
established during validation, may be chosen for analysis.
Specimens that fail to meet these requirements may be
analyzed at the laboratory director’s discretion, but these
specimens present some additional challenges that might
necessitate additional testing procedures or communication
in the report.
One of the issues with small specimens is the possibility
of false-negative results.45,115e117 The number of tumor
cells in comparison with normal tissue, such as inﬂamma-
tory and stromal cells, is an important factor that inﬂuences
the reliability of mutational analysis.115 This is particularly
important for less sensitive methods, such as unmodiﬁed
direct DNA sequencing. In such cases, it may be appropriate
to add to the report of a negative result a recommendation
for repeated testing on additional material if it becomes
available.
Although PCR-based methods can in principle detect
mutations from a single cell, a low copy number DNA
template can generate sequence artifacts, mainly guanine to
adenine transitions, due to stochastic occurrence of poly-
merase errors early in the PCR in the setting of low template.96
In addition, the DNA damage caused by formalin ﬁxation can
also lead to sequence artifacts.95 As much as 1 artiﬁcial
mutation per 500 bases may be observed in the analysis of
formalin-ﬁxed tissue with lowDNA content.97 The frequency
of errors reﬂects both TaqDNA polymerase’s normal error
frequency and the degree of damage and cross-linking of
DNA by formalin. For this reason, some laboratories perform
duplicate ampliﬁcations of FFPE samples to ensure accurate
results. For direct DNA sequencing, mutational artifacts
should be distinguished from true mutations by bidirectional
sequencing and by conﬁrmatory sequencing of independent
PCR products.107Whole genome ampliﬁcation is a method to
increase the amount of template DNA in insufﬁcient speci-
mens. It is prone to the same types of artifacts as PCRjmd.amjpathol.org - The Journal of Molecular Diagnostics
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analyze specimens in duplicate, beginning with a duplicate
whole-genome-ampliﬁcation step.118
Laboratories offering EGFR testing should determine the
requirements for each type of specimen they may encounter
(eg, ﬂuids, fresh tissues, ﬁxed tissues). All specimens from
a patient should be considered for testing, and the choice of
which specimen to test should be made by a pathologist
familiar with the molecular testing to be performed, based
primarily on tumor content and likely DNA quality as
inﬂuenced by ﬁxatives and other solutions used in histology.
If no adequate specimen is available and a new specimen
needs to be procured, then the decision regarding which
specimen to obtain is a complex one. Factors in this decision
include the patient’s overall health, accessibility of lesions,
radiographical appearance of lesions, and ability to schedule
procedures promptly. The pathology factors that contribute
to this decision include the minimum specimen require-
ments for each sample type, as well as the relative likelihood
of each sample type meeting these requirements. As such, it
is important for the molecular pathologist to monitor the
percentage of specimens that are being rejected as inade-
quate for each specimen type and to provide consultation to
the oncology care team to assist in obtaining the specimen
type that is most likely to yield a diagnostic result. Although
not a guideline recommendation, some pathology depart-
ments may send a cytopathologist or cytotechnologist to
provide immediate consultation in the clinic or interven-
tional radiology suite regarding adequacy of specimens
obtained by needle biopsy procedures.
5.2: Expert Consensus Opinion
Each laboratory should establish the minimum proportion
and number of cancer cells needed for mutation detection
during validation.
The minimum percentage tumor cellularity requirements
will depend on the methodology being used for analysis. In
general, a minimum mutated allele frequency of 25% (50%
cancer cell frequency, assuming heterozygosity and disomy)
is required for unmodiﬁed Sanger sequencing, although this
is a generalization and each laboratory must determine its
sensitivity cutoff for each assay.119 Several more sensitive
mutation detection techniques have sensitivities in the range
of 10% down to 1% or even lower.119e122 These are general
approximations, however, and each laboratory must deter-
mine theminimum amount of tumor cells needed for analysis
(analytic sensitivity) during validation, for each specimen
type that will be accepted by the laboratory (ﬁxed tissue,
fresh/frozen tissue, ﬂuid) and for each analyte measured.
Ideally, these studies are performed with patient specimens,
although cell lines may be necessary if appropriate patient
specimens are not available. The use of plasmids is not rec-
ommended owing to an increased risk for intralaboratory
contamination similar to that of PCR products.
Importantly, the association between mutated allele
content and cancer cell content is signiﬁcantly affected byThe Journal of Molecular Diagnostics - jmd.amjpathol.orggenomic copy number changes. EGFR-mutated alleles are
often ampliﬁed.123,124 While it might be ideal to determine
the EGFR copy numbers for the validation specimens (ie, by
FISH) and use disomic tumors for sensitivity assessment,
this may not be practical for most laboratories, in which case
the sensitivity studies should be performed with more than 1
specimen, to control for the variation in EGFR copies
between tumors or cell lines.
In addition to establishing the analytic sensitivity of the
EGFR testing method during validation, the performance of
the assay also needs to be monitored in an ongoing fashion
once clinical testing is initiated. Accordingly, a low-positive
control specimen (near the lower limit of tumor content of
specimens accepted by the laboratory) should be tested in
each clinical assay run.
5.3: Expert Consensus Opinion
A pathologist should assess the tumor content of each
specimen and either perform, or guide a trained technologist
to perform, microdissection for tumor cell enrichment as
needed.
Appropriate assessment of the specimen is critical for
accurate results and preventing false-negative results and
assay failures. A representative stained slide must be
reviewed by a pathologist to determine and document the
cellular content and tumor purity in the focus of tissue to be
tested. An ideal specimen would have not only a very high
proportion of malignant cells relative to the admixed non-
neoplastic cells, but also a minimal amount of substances
that may inhibit ampliﬁcation, such as mucin and necrotic
tissue. In general, assessment of tumor content and purity is
more accurate in ﬁxed sections than in frozen sections, and
this has prompted some laboratories to designate FFPE
tumor material as the preferred specimen type.
Estimates of tumor content from hematoxylin-eosine
stained sections vary considerably between pathologists.125
Establishing gold standard calibration specimens through
formal cell counting of selected areas can be used to train
pathologists and assess their accuracy and precision. In the
absence of a true standard, consensus opinion can be used to
assess tumor content in a specimen near the threshold for
acceptability.
Often, the entire tissue section may have a suboptimal
proportion of tumor for analysis, but a subregion within the
section may be more suitable, and an enrichment strategy
must be used to isolate cells from the more concentrated area
only. In this event, the tumor enrichment can be performed
directly by the pathologist or by a trained technologist under
guidance by the pathologist, in which case, the ideal region
should be demarcated on the slide by a pathologist during
their hematoxylin-eosin review of the case, with documen-
tation of tumor content, and used as a reference for the tumor
enrichment procedure. Tumor enrichment procedures should
also be assessed during test validation.
Dissection of areas rich in tumor cells from surrounding
normal tissue is the typical method for enriching a specimen429
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is the production of relatively pure specimens of a morpho-
logically conﬁrmed cell population. Dissection methods
include gross macrodissection or coring of an area out of
tissue or a parafﬁn block, microdissection from glass slides,
with or without visualization under a microscope, and ﬂow
cytometric sorting or laser capture microdissection (LCM)
techniques to enrich the specimen cell by cell. Manual
dissection is quick, relatively simple and requires inexpen-
sive equipment such as a standard or inverted microscope.
As different laboratories will have different resources
available for this step, any method can be adopted for tumor
enrichment, as long as the cellularity requirements for the
assay are established accordingly.
Laser capture microdissection is a time-consuming and
labor-intensive method that requires expensive equipment.
Although the actual microdissection is relatively simple,
personnel must be specially trained to use the equipment.
Another disadvantage of LCM is that DNA yield is often
low. The main advantage of this technique is that a pure cell
population with minimal normal tissue contaminants can be
acquired. Small specimens, such as endobronchial or needle
biopsies requiring LCM to isolate tumor cells, showed
a high failure rate (53%66%) by DNA direct sequencing
in contrast to larger resection or excisional biopsy speci-
mens (24%).126 In addition, LCM specimens typically have
low DNA content, which can lead to assay imprecision and
PCR artifacts that can be misinterpreted as unusual or novel
mutations96,127 (see “Question 6” discussion below).
Question 6: How Should EGFR Testing Be Performed?
6.1: Recommendation
Laboratories may use any validated EGFR testing method
with sufﬁcient performance characteristics.
Evidence Grade: B. Multiple test platforms are acceptable for
EGFR mutation testing, and this guideline does not
recommend any individual method(s) to the exclusion of
others. Rather, we recommend that tests offered for clinical
care meet speciﬁed minimal performance characteristics,
and require that laboratories establish acceptable perfor-
mance during validation and maintain acceptable quality
during production. The performance characteristics that are
most relevant for this discussion are sensitivity and speci-
ﬁcity. Other test characteristics of particular importance are
TAT and spectrum of mutations detected.
A variety of methods are used to detect EGFR mutations,
including Sanger sequencing with and without mutated allele
enrichment, the ampliﬁcation refractory mutation system,
length analysis, restriction fragment length polymorphism,
real-time PCR, high-resolution melting curve analysis, single-
base extension genotyping (including mass spectrometrye
based genotyping), and denaturing high-performance liquid
chromatography, each having different advantages and dis-
advantages27,36,57,115,120,121,128e156 (Table 11). At the time of430writing, published data on the application ofmassively parallel
sequencing to the detection ofEGFRmutationswere still quite
limited but this technology is expected to soon become more
widespread.157e159
6.2: Expert Consensus Opinion
Laboratories should use EGFR test methods that are able to
detect mutations in specimens with at least 50% cancer cell
content, although laboratories are strongly encouraged to
use (or have available at an external reference laboratory)
more sensitive tests that are able to detect mutations in
specimens with as little as 10% cancer cells.
The historical reference method, bidirectional sequence
determination by the Sanger method with ﬂuorescence-
tagged dideoxy terminators, is usually able to precisely
detectmutated sequenceswhen they constitute approximately
25% of the total DNA (potentially even lower for speciﬁc
nucleotide changes), which corresponds to a minimum tumor
content of approximately 50% for a heterozygous mutation
with no polysomy or ampliﬁcation.160 Although this method,
with this level of performance, was the initial method used to
establish the value of the test for predicting response of tumors
to erlotinib and geﬁtinib, many specimens fall short of this
tumor content.47,161,162 As a consequence, laboratories
exclusively using this method would have to reject a signiﬁ-
cant proportion of specimens as inadequate for testing.
All laboratories must establish the lower sensitivity of their
methodology during test validation. Any tumor enrichment
procedures, such as manual microdissection, must be
included as part of the validation. The sensitivity limit (also
called analytic sensitivity) should be deﬁned as the lowest
concentration of tumor cells in which a mutation is detected
with 100% precision in replicates repeated both within run
and between run.107 As stated earlier, because of possible
variation in the genomic copy number of mutated EGFR
alleles between tumors, this cutoff should be validated on
more than 1 tumor specimen. Wild-type results above this
limit can be reported conﬁdently as negative.
Although the published evidence supports a recommenda-
tion that anymethodmust be at least as sensitive as the Sanger
sequencing technique that ﬁrst established the clinical value
of mutation detection, our expert consensus opinion is that
more sensitive methods should be available, because of the
many patients who only have had samples with low tumor
content.115,163 In our opinion, an ideal test should be able to
detect mutations in specimens with as little as 10% cancer
cells. In particular, laboratories that use Sanger sequencing
are strongly encouraged to use a mutated alleleeenriching
strategy, such as locked nucleic acid or peptide nucleic acid
clamps, coampliﬁcation at lower denaturation temperature
PCR, or enzymatic digestion of wild-type sequences, to
enhance the sensitivity for the common critical mutations in
exon 19 (747_750 LREA deletions), 20 (T790M), and 21
(L858R).70,156,164 If a laboratory cannot offer amore sensitive
method than unmodiﬁed Sanger sequencing, then that labo-
ratory must communicate its limitation clearly to its cliniciansjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 11 Comparison of Sanger Sequencing to Other Methods for the Detection of EGFR Mutations
Sanger sequencing versus other
methods
Concordance
of methods, % n (N)
Seq/
otherþ
Seqþ/
other
Incidence of EGFR
mutations, %
RR (95% CI) P value
Sanger
sequencing
Other
method
PCR-based mutation detection
Allele-speciﬁc PCR/ARMS130 73 1 (83) 18 4 16 33 0.48 (0.27e0.87) 0.01
Real-time PCR119,304 97 2 (102) 2 1 26 27 0.94 (0.60e1.46) 0.78
Cycleave PCR131,* 95 1 (195) 1 8 40 36 1.10 (0.85e1.41) 0.47
Post-PCR mutation detection
Capillary electrophoresis296,304 98 2 (61) 1 0 16 18 0.91 (0.42e2.01) 0.82
Restriction fragment length
polymorphism133
99 1 (109) 1 0 33 34 0.97 (0.67e1.41) 0.89
INVADER305,y 86 1 (42) 5 1 43 52 0.82 (0.52e1.29) 0.39
Pyrosequencing159,306 96 3 (140) 6 0 16 20 0.78 (0.49e1.25) 0.30
Mutation scanning
Denaturing HPLC139,307 94 2 (196) 12 0 20 27 0.66 (0.27e1.63) 0.37
Single-stranded conformational
polymorphism45
98 1 (375) 8 0 8 10 0.79 (0.51e1.25) 0.32
High-resolution melting
analysis121,135,308
83 3 (321) 54 0 36 53 0.70 (0.46e1.06) 0.09
Loop-hybrid mobility shift assay309 100 1 (43) 0 0 26 26 1.00 (0.49e2.06) >0.99
Mutant enrichment
Peptide nucleic acid/locked
nucleic acid ampliﬁcation301,310
96 2 (150) 4 2 11 12 0.91 (0.49e1.67) 0.75
COLD PCR138 100 1 (126) 0 0 10 10 1.00 (0.48e2.07) >0.99
Smart Ampliﬁcation
Process120,132,301
86 4 (220) 30 0 20 34 0.58 (0.44e0.77) <0.001
The variation in EGFR mutation rate between rows may reﬂect studies performed in different patient populations (Asian versus non-Asian). No statistical
comparisons were performed between rows.
*Cycleave (Takara Bio, Otsu, Shiga, Japan).
yInvader (Hologic, Madison, Wisconsin).
ARMS, ampliﬁcation refractory mutation system; CI, conﬁdence interval; COLD, coampliﬁcation at low denaturation temperature; HPLC, high-performance
liquid chromatography; n, number of studies; N, number of patients; PCR, polymerase chain reaction; RR, relative risk, Mantel-Haenszel random effects model,
(95% CI); Seq, negative by Sanger sequencing; Seqþ, positive by Sanger sequencing.
Lung Cancer Molecular Testing Guidelinesand make available referral to another laboratory for more
sensitive testing for specimens with lower tumor content.
Although analytic sensitivity is very important for
expanding testing to patient specimenswith low tumor content
or purity, ultrasensitive molecular assays (deﬁned here as an
analytic sensitivity of below 1%) can be problematic. In
specimens with high tumor content, if an ultrasensitive
molecular assay ﬁnding is positive while an assay ﬁnding of
conventional sensitivity is negative, the result is either inter-
preted as a possible false positive due to mispriming or low
cross-contamination, or as a true positive reﬂecting a very
small mutated subclone. Thus, there is a risk of losing speci-
ﬁcity with regard to predicting response to targeted therapy.
Some studies using such methods have found novel, possibly
artifactual mutations, or failed to show a relationship between
classic EGFR mutations and treatment response.165 Finally,
technical artifactsmaybe seenwith ultrasensitivemethods that
require experience and caution in interpretation.
Accordingly, speciﬁcity of ultrasensitive methods must
receive additional attention during validation. Multiple nega-
tive lung cancer specimens should be tested, as should no-
template controls.Given the huge collective testing experienceThe Journal of Molecular Diagnostics - jmd.amjpathol.orgaccumulated and reﬂected in online databases such as the
Catalogue of Somatic Mutations in Cancer (COSMIC), novel
EGFR mutations are rare today, and the discovery of novel
mutations is cause for careful scrutiny and reevaluation of
methodology.Artifacts should be presented in the laboratory’s
standard test operating procedure manual to assist in inter-
pretation, and laboratories should clearly communicate with
clinicians when results are unclear or uncertain.
Although not a guideline recommendation, a suggested
approach is to offer a 2-tiered testing strategy, in which both
standard-sensitivity and high-sensitivity testing is performed
and reported. An example would be Sanger sequencing with,
and without, mutated enrichment by locked nucleic acid/
peptide nucleic acid. The report would then indicate whether
a mutation was detected only with the ultrasensitive method
or also by the less sensitive method, which could then be
correlated with the morphological estimate of tumor content.
Each laboratory should have a dialogue with its clinicians
to understand the TAT needs within its health care setting. If
results are needed within a few days, then multistep testing
such as Sanger sequencing may be less desirable than
a 1-step procedure such as allele-speciﬁc PCR. Similarly, if431
Lindeman et ala sample has borderline tumor content for the method in
question and TAT is critical, it may be better to go directly
to a more sensitive method or have the patient undergo
another sampling procedure, rather than attempt an analysis
that may end up with an inconclusive interpretation.
6.3: Expert Consensus Opinion
Clinical EGFR mutation testing should be able to detect all
individual mutations that have been reportedwith a frequency
of at least 1% of EGFR-mutated lung adenocarcinomas.
Another critical issue inmethod selection is the spectrum of
mutations tested. This is not a concern for Sanger sequencing,
which provides information on mutations throughout the
exons sequenced (usually exons 18 to 21), but it is an
important consideration in the selection or design ofmutation-
speciﬁc assays. The 2 most common mutations in EGFR, the
short in-frame deletions in exon 19 and the L858R point
mutation in exon 21, account for about 90% of all EGFR
mutations, and these are the mutations with by far the most
extensive data on EGFR TKI response rates (Table 12).
Nonetheless, response data are accumulating for other less
common mutations and therefore, our consensus opinion is
that limiting testing to the 2 major mutations is no longer
considered acceptable.
RoutineEGFR assays forEGFR exon 19 deletions should be
designed to detect not just the common 15-bp and 18-bp dele-
tions, but also the less common9-, 12-, 24-, and 27-bp deletions,
as well as the uncommon 15-bp and 18-bp insertions.166 EGFR
exon18 should be analyzed for E709 andG719mutations; exon
20 for S768, T790M, and insertions; and exon 21 for L858R,
T854, and L861Q mutations. Pretreatment T790M mutations
andmost exon 20 insertions are associatedwith lackof response
to ﬁrst-generation EGFR TKIs, and this should be communi-
cated in the report.137,167e169
Given the accumulated experience with EGFR mutations,
the detection of “novel”mutations or mutations only reported
very rarely should be viewed with great caution and should
prompt replicate assays on new DNA extracts to rule out
artifactual mutations due to formalin ﬁxation, PCR errors, or
whole-genome-ampliﬁcation errors (if used). Nevertheless,
rare variants and rare mutations will occur, and such ﬁndings
should not be automatically discarded as errors.
The recommendation for broad mutation detection may
conﬂict with the recommendation for TAT. In these instances,
laboratories may consider offering 2 assays: a rapid assay for
the most common mutations, which can be reported within
a few days in cases of clinical urgency, and a more compre-
hensive follow-up assay to detect the remaining mutations,
which may take longer to report.
6.4: Recommendation
Immunohistochemistry for total EGFR is not recommended
for selection of EGFR TKI therapy.
Evidence Grade: A. Interest in IHC-based testing is driven by
the fact that it is a technology available to essentially all432pathology departments, and it can be performed for
specimens where the number or proportion of tumor cells
poses challenges for molecular tests based on bulk DNA
extraction from tissue. There are 3 main types of EGFR
IHC: IHC for total EGFR, IHC for phosphorylated EGFR,
and IHC for mutated forms of EGFR.
Immunohistochemistry for total EGFR is not an acceptable
test for EGFR TKI treatment selection because it has been
shown to correlate poorly or not at all with the presence of
EGFRmutations.123,170,171 However, in other settings, the role
of IHC for total EGFR may need to be reassessed in the future
if the anti-EGFR monoclonal antibody cetuximab becomes
a therapeutic option in mutation-negative, EGFR-over-
expressing patients.172
Experience with IHC for phosphorylated EGFR is still
limited and concerns remain regarding the stability of
phosphorylation status in routinely handled pathology
material. Use of such IHC assays for EGFR TKI treatment
selection would be premature at this point.
The third type of IHC assay that has been evaluated
uses commercially available mutation-speciﬁc rabbit
monoclonal antibodies directed against the most common
mutated forms of EGFR: the 15-bp/5-amino acid deletion
(E746_A750del) in exon 19 and the L858R point mutation
in exon 21.173 In several independent studies,173e175 IHC
with the EGFR L858R mutated antibody has conﬁrmed
excellent sensitivity and speciﬁcity relative to mutation
testing. The EGFR exon 19 mutatedespeciﬁc antibody
showed excellent sensitivity and speciﬁcity for cases with
the 15-bp deletion in exon 19 but reduced sensitivity for
exon 19 deletions of other sizes.174,176e178 If scoring
cutoffs are set stringently to ensure a high positive
predictive value, IHC with EGFR mutationespeciﬁc
antibodies could be used as an initial screen to identify
most patients who are candidates for EGFR inhibitors;
however, for all specimens negative with these 2
mutation-speciﬁc monoclonal antibodies, that is, most
samples overall, molecular testing is still needed. In the
absence of an algorithm that includes molecular testing of
negative cases, mutated EGFR allele-speciﬁc IHC is
currently too insensitive to be used as a stand-alone assay
for EGFR TKI treatment selection. However, for patients
with only a low cellularity specimen deemed inadequate
for DNA analysis, this IHC may be the best option
available, but there is still no prospective clinical experi-
ence with this special situation.179 Overall, the body of
published data are insufﬁcient to make an evidence-based
recommendation regarding the use of EGFR muta-
tionespeciﬁc IHC at this time. Laboratories that plan to
use these antibodies clinically should validate their use
against a valid molecular assay, communicate their clin-
ical performance characteristics (eg, sensitivity, speci-
ﬁcity) to their clinicians, and make available referral to
another molecular laboratory for molecular testing to
exclude mutations in IHC-negative tumors (if not avail-
able in-house).jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 12 EGFR Mutations Accounting Individually for at Least 1% of All EGFR Mutations
EGFR exon EGFR codon
Mutations*
(amino acid) Nucleotide substitutions
Approximate % of all
EGFR mutations
18 E709 E709K c.2125G>A 1
E709A c.2126A>C
E709G c.2126A>G
E709V c.2126A>T
E709D c.2127A>C, c.2127A>T
E709Q c.2125G>C
G719 G719S c.2155G>A 2e5
G719A c.2156G>C
G719C c.2155G>T
G719D c.2156G>A
19 K739, I740, P741, V742, A743, I744 Insertions 1
18-bp ins
E746, L747, R748, E749, A750, T751, S752, P753 Deletions 45
15-bp del
18-bp del
9-bp del
24-bp del
12-bp del
20 S768, V769, D770, N771, P772, H773, V774 Insertions
3-bp ins
6-bp ins
9-bp ins
12-bp ins
5e10
S768 S768I c.2303G>T 1e2
T790 T790M c.2369C>T 2y
21 L858 L858R c.2573T>G 40
L858M c.2572C>A (rare)
L861 L861Q c.2582T>A 2e5
L861R c.2582T>G
All mutations listed are generally associated with sensitivity to EGFR TKIs except T790M and some exon 20 insertions. G719 and L861 mutations are
considered sensitive but somewhat less so than the major exon 19 and 21 mutations. Exon 20 insertions are variable in exact position and structure and EGFR
TKI response data remain very limited for some types of insertions. Mutations at E709 and S768 often occur in combination with another of the listed
mutations. Data derived from Chen et al110; He et al166; Oxnard et al210; Wu et al278; Bamford et al311; De Pas et al312; and Murray et al.313
*For each codon or region, missense mutations are listed in decreasing order of frequency; for less common missense mutations, this order is approximate.
For insertions or deletions, the codons most commonly involved are simply listed by cDNA order only.
yUp to 50% of T790M mutations detected in pre-treatment tumor samples may be germline mutations.
del, deletion; ins, insertion.
Lung Cancer Molecular Testing Guidelines6.5: Recommendation
EGFR copy number analysis (ie, FISH or chromogenic in
situ hybridization) is not recommended for selection of
EGFR TKI therapy.
Evidence Grade: B. Increased EGFR gene copy number
(polysomy or ampliﬁcation) is observed in about 40% of
cases, with a range of 8% to 66%.54,129,180e182 Across
multiple studies, the EGFR TKI response rates for patients
with EGFR polysomy/ampliﬁcation is 30% (Table 13),
consistently well below the mean response rate seen for
patients with EGFR mutations (68%) (Table 1).
Ampliﬁcation of the mutated EGFR allele is common and
drives a strong statistical association of EGFR polysomy/
ampliﬁcation with EGFR mutation.170,171 The correlation
of EGFR polysomy/ampliﬁcation with EGFR TKI response
is secondary to this strong association with EGFR
mutation, and in the cases where EGFR mutation and copyThe Journal of Molecular Diagnostics - jmd.amjpathol.orgnumber are discrepant, the mutation status is better
associated with EGFR TKI response.170,171 In studies with
data on both, EGFR TKI response rates for cases with
EGFR polysomy/ampliﬁcation and wild-type EGFR
sequence are very low, essentially in the range of EGFR-
nonmutated cases without increased EGFR copy
number.170,171 In contrast, EGFR-mutated cases lacking
ampliﬁcation show response rates comparable to EGFR-
mutated cases overall.170,171 Finally, comparisons of EGFR
ampliﬁcation and EGFR mutation as predictors of response
and clinical outcome in earlier clinical trials of TKI versus
placebo in the second-line (or greater) setting were
hampered by the small size of the subsets of patients with
available molecular data, in particular mutation data.4,6,163
The IPASS study, a large phase III randomized clinical trial
with data on both EGFR mutation and ampliﬁcation,
showed that EGFR TKI treatment selection based on
mutation status leads to better clinical outcomes in the433
Lindeman et alﬁrst-line setting than selection based on EGFR gene copy
number, and subsequently published large phase III
randomized controlled trials of TKI treatment response in
the ﬁrst-line setting used mutation analysis.7,26,90,91,183e185
Thus, EGFR copy number testing, whether by FISH or
chromogenic in situ hybridization, is less predictive than
mutation testing and should not be used as a method for
EGFR TKI treatment selection.170,171 More study is needed
to determine if mutated allele copy number is a modiﬁer of
beneﬁt in the setting of EGFR mutation.
Question 7: What Is the Role of KRAS Analysis in
Selecting Patients for Targeted Therapy With EGFR
TKIs?
7.1: Recommendation
KRAS mutation testing is not recommended as a sole
determinant of EGFR TKI therapy.
Evidence Grade: B. The most common (w30%) oncogene
mutated in lung adenocarcinomas is KRAS. The frequency
of KRAS mutations varies between ethnic groups; they are
less frequent in Asians (5%10%) when compared with
individuals of white European or white American ancestry
(25%-35%) and African ancestry (15%25%).25,186e188
Approximately 90% to 95% of patients with KRAS-
mutated lung adenocarcinomas have a history of tobacco
use and therefore, regional differences in the proportions
of KRAS-mutated lung adenocarcinomas may also reﬂect
variations in smoking prevalence, but KRAS mutations can
also be observed in approximately 5% of lung cancer
patients who never smoked tobacco.189,190 The substantial
cumulative clinical experience and published data have
shown that EGFR and KRAS mutations are mutually
exclusive.
Several studies compared response rates, PFS, and overall
survival in patients with KRAS-mutated lung cancer treated
with EGFR TKI, and 2 metaanalyses addressing these
questions have been reported.28,180,191e201 The association
between KRAS mutations and a lack of response to EGFR
TKI was based on retrospective reviews of EGFR TKI in the
second- and third-line setting.28,180,191e193,195e202 Objective
response to EGFR TKI can be seen in 0% to 3% of patients
with KRAS mutations and 26% of patients with KRAS wild
type.28,180,191e193,195e202
In part because of the ease of testing for KRAS codon 12
and 13 mutations and its widespread availability owing to
indications in metastatic colorectal cancer, testing for KRAS
mutations as a negative predictor of response to EGFR TKI
has become part of molecular diagnostic algorithms for lung
adenocarcinoma in many centers. However, with more
recent data showing that EGFR wild-type tumors have less
favorable outcomes if they are treated with EGFR TKI than
if they are treated with conventional platinum-based
chemotherapy, the decision to treat with an EGFR TKI can
no longer be made without an EGFR result, and the role of434KRAS testing in this context has diminished.26,90,91 The
signiﬁcance of KRAS mutational analysis may become
increasingly important with the further development of new
therapies targeting downstream RAS pathways such as PI3K/
AKT/mTOR and RAS/RAF/MEK, but at this time, the
absence of a KRAS mutation does not add clinically useful
information to the EGFR mutation result and should not be
used as a determinant of EGFR TKI therapy. However,
because KRAS and EGFR mutations are mutually exclusive,
a rapid and inexpensive KRAS assay may be performed
initially to exclude KRAS-mutated tumors from EGFR
mutation testing as part of an algorithm designed to maximize
testing efﬁciency, provided that the sample is sufﬁcient to
perform the KRAS test without sacriﬁcing EGFR and ALK
testing, and that the totality of clinically relevant molecular
results can be obtained within the target TAT.
There are other clinical settings in which KRAS mutation
has been examined as a biomarker that are not directly related
to the present guidelines. In patients without EGFRmutations
for whom chemotherapy fails, erlotinib may be administered
as a second-line agent. In these patients, KRASmutation may
presage a poorer outcome, although the evidence for this from
the BR21 trial is limited by small sample size and lack of
statistical signiﬁcance.170 KRAS testing is also not predictive
of beneﬁt (or lack of beneﬁt) from cetuximab therapy in lung
cancer patients.172,203
Question 8: What Additional Testing Considerations
Are Important in the Setting of Secondary or Acquired
EGFR TKI Resistance?
8.1: Recommendation
If a laboratory performs testing on specimens from patients
with acquired resistance (AR) to EGFR kinase inhibitors,
such tests should be able to detect the secondary EGFR
T790M mutation in as few as 5% of cells.
Evidence Grade: B. Although clinical and radiographical
responses to EGFR TKIs in patients with “sensitizing” EGFR
mutations are signiﬁcant in approximately 70% of cases, these
patients almost invariably experience recurrence or progression
while on treatment after a median of 8 to 16 months, a clinical
phenomenon termed acquired resistance.137,204e206 Clinical
management implications of AR mechanisms are still
evolving without established treatment guidelines; additional
tumor material may be procured in this clinical setting in the
course of diagnostic or therapeutic procedures, such as
biopsies, to conﬁrm recurrence or metastasis, or management
of malignant effusions. In the event that tumor specimens
from AR patients are tested, the following suggestions are
included in this guideline.
The most common mechanism of AR involves the emer-
gence of an additional EGFR tyrosine kinase domain mutation,
T790M, caused by a single base substitution, C to T, at nucle-
otide 2369; this mutation is found as a second mutation on the
EGFR allele harboring the initial “sensitizing” EGFRjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 13 Different Outcomes of Tyrosine Kinase Inhibitor Therapy for Patients Tested by EGFR Fluorescence in Situ Hybridization (FISH)
Outcome
Mean  SD Percentage
n (N)
Risk ratio M-H,
random (95% CI) P value
EGFR FISHþ
(high copy no.)
EGFR FISH
(low copy no.)
EGFR FISHþ
(high copy no.)
EGFR FISH
(low copy no.)
Response rate, %* 30 9 11 (861) 2.69 (1.86e3.90) <0.001
Disease control rate, %y 47 24 5 (438) 2.09 (1.63e2.69) <0.001
Overall survival at 1 y, %z 68 37 1 (183) 1.83 (1.37e2.44) <0.001
Time to progression/
progression-free
survival, mox
4.4  2.8 2.9  0.7 7 (638) 4.06 (1.97e6.16) <0.001
Median survival time, mo{ 10.3  3.4 8.7  2.4 8 (778) 1.54 (1.83 to 4.91) 0.37
FISH scored according to the criteria of Cappuzzo et al.251
*References 28, 180, 191, 193, 195, 197, 198, 251, 314e316.
yReferences 191, 193, 195, 279, 314.
zReference 193.
xReferences 28, 185, 191, 193, 251, 316, 317.
{References 28, 180, 185, 191, 193, 197, 316, 317.
CI, conﬁdence interval; M-H, Mantel-Haenszel; n, number of studies; N, number of patients; Random, random effects model; SD, standard deviation.
Lung Cancer Molecular Testing Guidelinesmutation.137,168,207 Because AR is, within the tumor cell pop-
ulation, a subclonal process, that is, it is driven by the selection
and outgrowth of a subclone of tumor cells that harbor T790M
that confers a survival advantage in the presence of EGFRTKI,
the technical sensitivity of the detection method is even more
critical than in the testing for baseline, sensitizing EGFR
mutations that are present in every tumor cell. Initial reports
found this mutation in approximately 50%of tumors at the time
of treatment failure.137,168 However, because T790M is often
not present in every tumor cell, conventional Sanger
sequencing, even with microdissection, is considered insufﬁ-
cient for this testing.207 More recent studies based on higher
sensitivity approaches place the prevalence of T790M in AR
samples in the 60% to 70% range.208 In vitro studies have
shown that cell populationelevel EGFR TKI resistance
becomes detectable in the presence of as little as 5% T790M-
bearing cells and, in the absence of further clinical data, our
consensus opinion is that assays for T790M should have
sensitivity to detect mutations in 5% of cells.209 This means
that unmodiﬁed Sanger sequencing alone is insufﬁcient, and
laboratories using Sanger sequencing should consider
a mutation-enriching strategy such as peptide nucleic acid/
locked nucleic acid clamps, or have amore sensitive assay (eg,
allele-speciﬁc PCR) that targets the T790M mutation in the
setting of AR.
Most studies have only rarely detected T790M in pretreat-
ment samples.210 When it is detected in the pretreatment
setting, it should be conﬁrmed as either somatic or germline by
testing of normal DNA from the patient. Germline T790M
mutation has been associated with familial lung cancer, and
therefore its detection should trigger evaluation of the family
history and genetic counseling, keeping in mind that risk
estimates and screening recommendations for unaffected
T790M carriers remain to be determined.210,211
Other rare second-site mutations in the EGFR tyrosine
kinase domain have been described in AR specimens,
including L747S, D761Y, and T854A, but owing to theirThe Journal of Molecular Diagnostics - jmd.amjpathol.orgrelatively low prevalence, there is not much clinical expe-
rience with these and insufﬁcient data have been published
to formulate an evidence-based recommendation.212
A less common mechanism of EGFR TKI resistance is
ampliﬁcation of another receptor tyrosine kinase, most often
MET or ERBB2. In initial reports, MET ampliﬁcation was
reported in up to 20% ofAR cases, with a portion of these also
harboring the EGFR T790M mutation, but more recent
studies suggest this number is closer to 10%.71,204,213,214
However, there is currently a lack of a precise deﬁnition of
clinically signiﬁcant MET ampliﬁcation in this setting and
more research is needed before guidelines can be formulated.
More recently, ERBB2 ampliﬁcation has been reported in
another subset of AR cases.318
Several clinical trials aimed at overcoming these distinct
mechanisms of AR are underway and it is therefore likely that
the further management of these patients will soon require
determining T790M status and ampliﬁcation of other receptor
tyrosine kinases. T790M status may also become important in
determining whether ﬁrst-line EGFR TKIs should be
continued in patients with AR. Recent data suggest that AR
patients with the T790M mutation can derive continued
clinical beneﬁt from the ﬁrst-line EGFR TKI.209,213
Interestingly, SCLC histology and associated “SCLC-
type” radiosensitivity and chemosensitivity have been
observed in some AR cases, further supporting the notion that
biopsy of recurrent tumor can be clinically valuable in AR.213
Section III: How Should ALK Testing Be
Performed?
Question 9: What methods should be used for ALK
testing?
9.1: Recommendation
Laboratories should use an ALK FISH assay using dual-
labeled break-apart probes for selecting patients for ALK435
Lindeman et alTKI therapy; ALK immunohistochemistry, if carefully
validated, may be considered as a screening methodology to
select specimens for ALK FISH testing.
Evidence Grade: B. The genetic alteration of ALK in lung
adenocarcinoma is due to chromosomal rearrangement. The
most common of these rearrangements involves a pericentric
inversion on the short arm of chromosome 2, inv(2)(p21p23),
which creates a fusion gene encoding the amino-terminal
portion of EML4 (2p21) and the intracellular region of ALK
(2p23), genes that are normally approximately 13 Mb
apart.8,215 Although the EML4-ALK fusion is the most
common, other less common variant fusions have been
reported, including translocations with other chromosomes
(KIF5B-ALK, TFG-ALK ).215,216 The NPM-ALK translocation
that has been well characterized in anaplastic large cell
lymphoma (for which the gene was named) has not been
reported in lung cancer.
FISH was the methodology used in the initial studies that
demonstrated improved clinical response of patientswithALK-
rearranged tumors to treatment with crizotinib, a targeted ALK
TKI.15,17,217 Although FISH assays have been developed by
using both break-apart and fusion strategies, the break-apart
assay design has shown the best association with clinical
outcome.12,218 A commercial assay (AbbottMolecular Probes,
Abbott Park, Illinois) is available that contains a SpectrumOr-
ange-labeled 300-kb probe on the telomeric 30 side ofALK and
a SpectrumGreen-labeled 442-kb probe on the centromeric 50
side.With this probe set, thewild-type conﬁguration appears as
a fused yellow signal, while ALK rearrangement is seen as
distinct and separated orange and green signals (Figures 1, 2, 3,
and 4). In the US, FDA has approved this commercial assay as
a “companion diagnostic” to select patients to receive an FDA-
approvedALKTKI. The published evidence indicates that this
FISH assay is an acceptable means of selecting patients for
treatment with an ALK TKI.
Whether or not the FDA-approved commercial assay is
used, for accurate and precise results, the probe set used for
clinical testing should be characterized in detail and the
signal conﬁgurations and cutoff values for detecting ALK
rearrangement should show reproducible performance with
normal controls and known abnormal patient specimens and
cell lines. If another set of probes or assay design is used,
validation studies should demonstrate comparable or supe-
rior performance when compared to the commercial probes
with regard to signal intensity, magnitude of signal splitting
in positive cases, analytic precision, clinical sensitivity, and
clinical speciﬁcity in accordance with published stan-
dards.219,220 For laboratories that elect to use laboratory-
developed probes for ALK FISH testing, attention should
also be given to batch variability of clones, DNA-labeling
enzymes, and other reagents. Moreover, any laboratory-
developed tests should retain the ability to detect variant
fusions of ALK with partners other than EML4.
IHC-mediated identiﬁcation of lung adenocarcinomas
with overexpression of ALK has been investigated as436a simpler, quicker, and cheaper alternative to FISH-based
identiﬁcation of ALK rearrangements. However, IHC studies
using the anti-ALK1 antibody typically used for anaplastic
large cell lymphoma (mouse monoclonal anti-human
CD246, clone ALK1) have been disappointing, likely due
to the low expression level of the fusion protein in ALK-
rearranged lung adenocarcinomas in comparison to
anaplastic large cell lymphoma.11,79,216,221e223 A substantial
proportion of ALK-rearranged lung adenocarcinomas are not
identiﬁed by the ALK1 antibody, using standard techniques,
and thus it is not reliable for ALK rearrangement screening in
this setting.
To improve the sensitivity of detection of the ALK rear-
rangement by IHC with the commercially available ALK1
antibody, some groups have developed alternative methods,
including an intercalated antibody-enhanced polymermethod,
tyramide ampliﬁcation, and an enhanced polymer-based
detection system, with subsequent triaging of equivocal
cases forALK FISH.15,216 The current data are still limited and
more studies need to be published to recommend this approach
with this antibody.
A different antibody to ALK (mouse monoclonal, clone
5A4) has been reported to have excellent sensitivity and
speciﬁcity relative to ALK FISH results, at least for strong
IHC staining and for negative or weak IHC staining, while
intermediate IHC staining results were poorly predictive of
ALK rearrangement status.221 High sensitivity, speciﬁcity,
and reproducibility, as compared to FISH, have been shown
with 2 rabbit monoclonal anti-human ALK antibodies
(clones D5F3 and D9E4), and the former, ALK antibody
D5F3, has just recently become commercially available.221
Based on promising recent results with these newer
monoclonal antibodies, IHC assays hold the potential to
facilitate the routine identiﬁcation of ALK-rearranged lung
adenocarcinoma. Where sensitive IHC assays are available,
our consensus opinion is that a properly validated IHC
method may be used as a screening modality, and that
tumors that fail to demonstrate ALK immunoreactivity with
a sensitive IHC method need not be tested for ALK rear-
rangement by FISH. The use of sensitive ALK IHC assays
as screening tests has been adopted in some countries. Our
opinion is that tumors that are positive for ALK IHC, either
weakly or strongly, should still be referred to FISH for
conﬁrmation of a rearrangement. At this time, there are
insufﬁcient data available to develop a speciﬁc recommen-
dation on the use of ALK IHC as a sole determinant of ALK
TKI therapy.
9.2: Recommendation
RT-PCR is not recommended as an alternative to FISH for
selecting patients for ALK inhibitor therapy.
Evidence Grade: B. RT-PCR is not currently recommended as
a ﬁrst-line diagnostic method for determining ALK fusion
status because of concerns for a higher failure rate of an
RNA-based assay in routine FFPE pathology material, andjmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Negative forALK rearrangement (original magniﬁcation 1000). Figure 3 Positive for ALK rearrangement (single 30 ALK) (original
magniﬁcation 1000).
Lung Cancer Molecular Testing Guidelinesthe risk of false negatives, owing to variability in the EML4-
ALK fusion structure and the existence of other ALK fusion
partners. To date, there have been at least 13 molecular
variants of EML4-ALK reported, representing chimeric
transcripts fusing EML4 exons 2, 6, 13, 14, 15, 17, 18, or 20
to ALK exon 20 or immediately upstream within intron 19
of ALK.222 Fusion of ALK to TFG and KIF5B has been
reported in 1 case each, raising the likelihood that additional
variant fusions may exist.215,216,224 It is possible to design
multiplexed RT-PCR assays or to use multiple pairs of
primers in separate or sequential reactions to detect the
different EML4-ALK variants but multiplexed assays can be
difﬁcult to optimize and multiple separate assays may
require more RNA than can be regularly extracted from
small FFPE samples.
9.3: Expert Consensus Opinion
A pathologist should be involved in the selection of sections
for ALK FISH testing, by assessing tumor architecture,
cytology, and specimen quality.
Because cells are analyzed individually for evidence of
ALK rearrangement using a ﬂuorescence microscope, tumor
percentage is not as critical for ALK FISH testing as it is for
EGFR mutation testing. For ALK FISH, it is important toFigure 2 Positive for ALK rearrangement (split 30 ALK-50 ALK) (original
magniﬁcation 1000).
The Journal of Molecular Diagnostics - jmd.amjpathol.orgchoose slides or regions of slides in which the tumor cells can
be readily distinguished from admixed normal cells under
ﬂuorescence, typically through a combination of cytologic
and architectural features that can be appreciated without
stains or visualization of cytoplasm. In addition, areas should
be chosen in which tumor cells are not overlapping one
another.
Specimen requirements for ALK FISH are generally
similar to those for EGFR mutation testing: formalin ﬁxa-
tion is acceptable, specimens should have enough cancer
cells to analyze clearly, and DNA-damaging ﬁxatives or
acidic decalcifying agents should be avoided, as should
specimens with abundant necrosis. Unlike EGFR mutation
testing, however, FISH testing can be problematic when
performed on alcohol-ﬁxed samples. Another important
distinction between ALK FISH and EGFR mutation analysis
is that FISH testing should ideally be performed on recently
cut sections, although protocols can be adapted to older
slides.
Laboratories may follow the standard operating proce-
dures that have proven to be successful for FISH on
formalin-ﬁxed, parafﬁn-embedded tissue sections in their
setting. Attention must be paid to particular steps in theFigure 4 Negative for ALK rearrangement with ALK high copy number
(original magniﬁcation 1000).
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Lindeman et alprotocol that may affect probe penetration and hybridization
to target DNA to optimize signal intensities.
Particular attention should be paid during validation to
the choice of glass slides used for FISH. Several types of
slides are manufactured for specialized applications at the
expense of suitability for FISH. For example, some slides
designed for tissue microarrays have a heavy coating that
generates a ﬂuorescent matrix where tumor cells get
embedded and cannot be properly treated for FISH-probe
penetration. Other slides are designed for microdissection
and do not hold the tissue adequately during pretreatment
for FISH.
Modiﬁcations in the protease digestion protocol may
be required, depending on the size of the tissue, duration
and type of ﬁxation, nuclear structure and tissue pres-
ervation, and time between sectioning and digestion.
This may be particularly valuable with difﬁcult sections,
including cytology specimens and samples from bone
biopsies. Tissue digestion should be standardized to
maintain nuclear morphology. Overdigested chromatin
may display artifactual “split signals” that may lead to
false-positive ﬁndings.
Hybridization and washing steps should be standardized
by using established protocols. Use of automated tissue
processors and standardized commercial tissue digestion
kits can improve consistency and should be considered.
9.4: Expert Consensus Opinion
A pathologist should participate in the interpretation of ALK
FISH slides, either by performing the analysis directly or by
reviewing the interpretations of cytogeneticists or technol-
ogists with specialized training in solid tumor FISH
analysis.
The selection of nuclei to analyze is a step that is distinct
from the scoring of probe signals. When evaluating the
results of FISH, several factors should be kept in mind: the
architecture of the tissue, including local variations in
neoplastic cell content, ﬁxation, and tumor cellularity within
the section; the frequent presence of truncated nuclei; and
the complex nature of cytogenetic arrangements such as
heterogeneous increases in ploidy and aneusomy often seen
in lung cancer. The FISH technologist should work closely
with a pathologist who can identify tumor-rich areas.
Typically, areas selected for FISH evaluation will be
marked on a hematoxylin-eosinestained slide that is
directly parallel to the section used for FISH. Areas of the
FFPE section selected for signal scoring should pass
rigorous quality criteria as being suitable for FISH analysis.
Inclusion of macrophages or other nontumor cells in the
analysis will dilute positive break-apart scores and can lead
to false-negative results. Experienced scorers who have
undergone speciﬁc training in FISH in solid tumors should
analyze the slides. The scorers should also have had training
on the morphological appearance of lung cancer, and should
have easy access to assistance from a pathologist with
training in FISH. Laboratories with experienced reviewers438may use 1 scorer in cases with clearly negative or positive
(>50% of cells) cases and a second scorer for less clear
cases; otherwise 2 independent reviewers are recommended.
Interpretation should be performed in areas of the slide
with good signal, in which at least 50% of all nuclei are
easily analyzable, with minimal background or nuclear
ﬂuorescent “noise.” The FISH signal intensity should be
consistently greater than background intensity in the regions
of the slide chosen for analysis. Areas where the borders of
individual nuclei are not clearly identiﬁable and/or high cell
density causes excessive nuclear overlap are easy to
misinterpret, and should be avoided. At the same time that
the quality of the tissue section is reviewed, the FISH
signals should be assessed, looking for areas with bright,
distinct signals and low background in which individual
nuclei are clearly distinguishable. Signals in a nucleus
should in general have the same intensity and the DAPI
staining should be uniform.
Importantly, the interpretive criteria of FISH assays for
ALK rearrangement in lung carcinoma are not necessarily
identical to those applied in other neoplastic diseases (eg,
anaplastic large cell lymphoma, inﬂammatory myoﬁbro-
blastic tumor), even if the identical FISH probe set is used.
The most common positive result of a break-apart dual-
labeled FISH assay in lung cancer will result in 1 separate
orange/red and 1 separate green signal (Figure 4). The
native unaltered ALK region will remain as a yellow fusion
signal but also commonly appears as 2 narrowly split
orange/red and green signals. The second most common
positive result in lung cancer is loss of the green 50 probe
with a remaining unpaired 30 orange/red probe, indicating an
unbalanced rearrangement. Importantly, proper interpreta-
tion of the FDA-approved commercial break-apart assay
considers only nuclei with loss of a green signal, or orange/
red and green signals that are separated by a gap larger than
2 signal diameters, to be indicative of an ALK gene rear-
rangement. Split signals of lesser magnitude separation are
seen in the absence of ALK rearrangement and should not be
interpreted as positive.15 The identiﬁcation of a 2-diameter
gap by readers requires experience, and inclusion of well-
characterized negative and positive control sections is an
essential part of validating the assay.
Other observations likely to be encountered when scoring
signals include extra isolated 30 ALK signals as well as extra
signals (split and/or fusion) arising from polysomies, ploidy
changes, andmore complexALK rearrangements.15Currently,
these ﬁndings are of uncertain signiﬁcance. All results should
be entered onto score sheets and should be coded.
In the trials demonstrating ability of ALK FISH to
predict treatment response, a case was considered positive
if 15% or more of 50 nuclei assessed in a tumor-rich
portion of the section showed the classic split-signal
pattern.15,217 Therefore, this cutoff is suggested and is
part of the labeling of the FDA-approved commercial
assay. Laboratories should still validate clinically sensi-
tive and speciﬁc cutoffs in their own hands and differentjmd.amjpathol.org - The Journal of Molecular Diagnostics
Lung Cancer Molecular Testing Guidelinescutoffs must be reconciled with those from the commer-
cial reference method. In certain situations with low
tumor cell content, cutoffs as low as 5% may be consid-
ered, especially if IHC or RT-PCR results are available to
support it, but this area requires more study.
Limited data exist to recommend cutoff values for the
other “nonclassic” patterns of ALK rearrangement, such as
loss of 50 signal, and all testing laboratories should establish
their own cutoff values for these other patterns.
9.5: Expert Consensus Opinion
Testing for secondary mutations in ALK associated with
acquired resistance to ALK inhibitors is not currently
required for clinical management.
Several groups have reported a diverse set of secondary
mutations in ALK that confer acquired resistance to crizo-
tinib, including L1152R, C1156Y, F1174L, L1196M,
L1198P, D1203N, and G1269A.225e230 To date, however,
the numbers of such cases are too small to recommend
testing for these mutations for routine clinical management,
although we anticipate this indication to grow in the near
future as effective second-line therapies become available.
Section IV: Should Other Genes Be Routinely
Tested in Lung Adenocarcinoma?
Question 10: Are Other Molecular Markers Suitable for
Testing in Lung Cancer?
10.1a: Recommendation
Testing for EGFR should be prioritized over other molecular
markers in lung adenocarcinoma.
10.1b: Suggestion
After EGFR testing, testing for ALK should be prioritized
over other proposed molecular markers in lung adenocar-
cinoma, for which published evidence is insufﬁcient to
support testing guideline development at the present time.
Evidence Grade. EGFR: A; ALK: C: Many additional
molecular markers have been proposed as having value in
management of lung cancer, in a variety of settings, including
exposure to other molecularly targeted therapies, traditional
chemotherapy, radiation, or surgery, as well as in other stages
of disease and other histological types of lung cancer. For
each of these molecular markers, insufﬁcient data have been
published to establish deﬁnitive recommendations as to
where, when, and how they should be used. However, as
discussed in the sections above, clear and compelling pub-
lished evidence supports the need for EGFR and ALK testing
of advanced-stage lung adenocarcinomas as prerequisites to
treatment with targeted TKIs. Precious tumor tissue must
be reserved for these analyses, before any other molecular
analysis is considered. Other tests may be performed in
clinical trials or in clinical-pathological contexts deemed
appropriate by agreement between pathologists andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgclinicians at each individual treatment center, provided
sufﬁcient material remains after the essential EGFR and
ALK tests are completed.Section V: How Should Molecular Testing of
Lung Adenocarcinomas Be Implemented and
Operationalized?
Question 11: Must All Adenocarcinomas Be Tested for
Both EGFR and ALK?
11.1: Expert Consensus Opinion
Laboratories may implement testing algorithms to enhance
the efﬁciency of molecular testing of lung adenocarcinomas,
provided the overall TAT requirements are met.
Currently, the higher costs and labor of simultaneous
testing make it difﬁcult to implement, despite its obvious
advantage in TAT. Stepwise-testing algorithms make more
efﬁcient use of resources, but pose a challenge for timely
delivery of ﬁnal results. Given this time constraint, we
recommend that stepwise-testing algorithms, if used, should
nonetheless be completed within 10 working days. These
algorithms are based on the observation that EGFR, ALK,
and KRAS alterations are mutually exclusive, with very rare
reported exceptions.217,231,232
The simplest algorithm would be to test for EGFR
mutations ﬁrst and proceed to ALK FISH if the EGFR
results are wild type.
An alternative algorithm would involve an initial sensitive
and rapid EGFR mutation screening test by a method such as
denaturing high-performance liquid chromatography, high-
resolution melting analysis, or single-stranded conforma-
tional polymorphism. Depending on assay design, these rapid
screening methods could detect a mutation but fail to charac-
terize it completely (ie, fail to deﬁne the size of an exon 19
deletion or distinguish between L858R and L861Q point
mutations) or may be affected by single nucleotide poly-
morphisms (SNPs). For samples in which a mutation is
detected but not adequately characterized by a screening
method, a more speciﬁc method, such as sequencing, would be
performed to establish a deﬁnitive diagnosis. If the EGFR
mutation screening test result is negative, then testing for ALK
FISH should be performed. This involves an additional step,
but would reduce the amount of deﬁnitive EGFR and ALK
FISH testing considerably.
A third algorithm, slower still but potentially more
cost-effective, would begin with a simple KRAS analysis.
KRAS-mutated tumors, which represent 25% to 30% of lung
adenocarcinomas and which do not have either EGFR muta-
tions or ALK rearrangements, would not proceed to either
EGFR or ALK testing. The tumors without KRAS mutations
would then enter into one of the algorithms above. If used, such
an approach should stillmeet the aboveTAT recommendations
and should not be undertaken if the KRAS testing will exhaust
the sample and thereby preclude EGFR and ALK testing.439
Lindeman et alWhether or not to use any of these, or other testing
algorithms, is a decision that each testing laboratory must
make, in conjunction with its clinical care team, to balance
its available resources and clinical needs within its indi-
vidual health care setting.
Question 12: How Should EGFR and ALK Results Be
Reported?
12.1: Expert Consensus Opinion
EGFR mutation testing reports and ALK FISH reports
should include a results and interpretation section readily
understandable by oncologists and by nonspecialist
pathologists.
Oncologists should be able to readily glean the information
needed to select appropriate therapy, and to explain the result
to their patients. Pathologists should be able to learn sufﬁcient
details from the reports to help determine whether repeated
testing is appropriate, or to help resolve discrepancies between
clinical and laboratory results or between tests performed at
different laboratories.
The preclinical section of reports should include the
standard identiﬁers of the patient and specimen, as well as
an assessment of the specimen’s morphological character-
istics: diagnosis and tumor content (percentage of total
nuclei that are malignant). In addition, histopathological
characteristics that may affect the interpretation should be
mentioned, such as extensive necrosis, atypical specimen
processing or ﬁxation, or low total number of tumor cells.
The results section of reports should include, prominently,
the names of any clinically signiﬁcant mutations identiﬁed, in
formal Human Genome Variation Society (HGVS) nomen-
clature. Additional, more commonly used terminology may
be included, as requested by each institution’s clinical care
teams. Incidental ﬁndings, variants of uncertain signiﬁcance,
and benign polymorphic variants should be clearly presented
as such, to leave the reader no doubt as to the lack of evidence
supporting their role in clinical management. For multiplexed
assays, ideally, results could be presented in a table listing
each clinically signiﬁcant variant that is assessed by the test,
with an adjacent result for each. Inconclusive results should
be clearly reported as such.
Reports should include a histopathological assessment of
tumor content for the tumor section tested and the reported
result should include an overall statement of the cancer’s
likelihood to respond or resist EGFR TKI therapy. If the
result is inconclusive, whether due to assay failure or an
insufﬁcient specimen, or another reason, the interpretation
should state why (as best as is known) and suggest
requirements for testing a different specimen that would be
more likely to yield a successful result.
The technical section of the report should include enough
information for another laboratorian to understand what was
done, in the event of a discrepancy between laboratories, or
when requested to retest in another laboratory. The basic
methodology should be reported, along with the assay440sensitivity. For sequencing assays, each exon sequenced
should be listed; for targeted mutation assays, each mutation
targeted should be listed. Standard language regarding FDA
oversight of laboratory-developed tests should be used, as
appropriate.
The same overall principles apply to ALK reports, with
a few distinctions. The results section should also include the
number of cells analyzed, and the number and percentage of
cells with each ﬁnding. Proper International System for
Human Cytogenetic Nomenclature (ISCN) nomenclature
may be used but, perhaps even more so than for HGVS
nomenclature and molecular test results, ISCN nomenclature
is difﬁcult for the nonspecialist to understand, and colloquial
nomenclature is essential for clear communication of results.
Question 13: How Should EGFR and ALK Testing Be
Validated?
13.1: Expert Consensus Opinion
EGFR and ALK testing validation should follow the same
guidelines as for other molecular diagnostics and FISH tests.
Technical validation, the set of experiments performed in
the clinical laboratory to assure that an assay is safe and
reliable for use in patient care, is required in the United
States under the Clinical Laboratory Improvement Amend-
ments of 1988 (CLIA ’88). Although the required procedures
differ between laboratory-developed tests and FDA-
approved commercial assays, all tests must be properly
validated before introduction into clinical use.233 The CAP
has published recommendations and examples on validation
for a variety of assays.234e239 This section will focus on
speciﬁc points in the validation that the panel believes are of
particular emphasis for EGFR and ALK validation.
Validation samples should be of all types that will be
subjected to testingdfrozen, fresh, and ﬁxed specimens
(including each ﬁxative to be used), as appropriate. However,
it is not necessary to separately validate identically processed
tissues of different origins (ie, not necessary to validate
separately FFPE lung, FFPE lymph node, and FFPE brain).
All relevant mutations or rearrangements that are to be re-
ported should be included in the validation set, to whatever
extent is possible.While some rareEGFRmutationsmay not be
obtainable, the common exon 19 deletions, L858R, T790M,
G719, and exon 20 insertions are required. Similarly, ALK-
positive cases with split signals and with loss of 50 signals
should both be included in validation sets. It is not necessary to
separately validate each individual mutation in each specimen-
processing type, although it is recommended that each type of
mutation (ie, pointmutation, deletion, insertion, split signal, loss
of signal) be assessed in each specimen-processing type, if
possible. Cell lines may be used, but not to the exclusion of
clinical specimens except for rare mutations.
Precision studies should assess the reproducibility of the
entire analytic process, beginning with the pathologist’s
tumor assessment and enrichment strategies (eg, dissection).
Operationally, therefore, when validation specimens undergojmd.amjpathol.org - The Journal of Molecular Diagnostics
Lung Cancer Molecular Testing Guidelinesrepeated testing on different assay runs, those samples should
be reexamined by a pathologist and redissected.
Accuracy of results is best assessed by comparison with
another laboratory performing a properly validated assay.
Similarly, a new method within a laboratory may be vali-
dated against a previously validated method in the same
laboratory. Comparison with clinical history of treatment
response is suboptimal, but may be used as evidence of true
positive mutated specimens, in the absence of another
accredited laboratory for comparison. This should not be an
issue in the United States, where many CLIA-certiﬁed
laboratories offer these tests.
Analytic sensitivity of EGFR testing should be assessed in
DNA from mutated specimens with low tumor content,
diluted both in water/buffer and in normal DNA, to determine
tumor cell content, in terms of both absolute cell count and
tumor percentage, at which accuracy and precision (repro-
ducibility) deteriorate. The need for replicate measurements
to improve accuracy as tumor content decreases should be
determined thus. Because of variation inEGFR copy number,
sensitivity studies should be done with more than 1 specimen,
and the least sensitive result should be stated as the overall
test sensitivity. Cell lines are not ideal substitutes for clinical
specimens, although FFPE cell pellets may be helpful,
especially for mutations that are difﬁcult to obtain. The
sensitivity for FFPE specimens may differ from that for
specimens ﬁxed in alcohol or frozen.
Analytic speciﬁcity studies should establish criteria for
distinguishing between true-positive and false-positive
results. Speciﬁcity of EGFR and ALK results should be
conﬁrmed by clinically validated Sanger sequencing and
Abbott Vysis ALK Break Apart FISH Probe Kit, respec-
tively, or by methods traceable to those methods.
No template controls and very-low-concentration wild-
type specimens are essential to establish speciﬁcity of
ultrasensitive EGFR mutation detection methods. Artifacts
associated with ultrasensitive methods should be recorded in
the standard operating procedure manual.
ALK FISH should be performed on clearly benign tissue as
well as ALK wild-type tumors, to help establish the minimum
frequency of split signals that can be reported as true positive,
as well as to conﬁrm the 2-probe-diameter minimum distance
of signal splitting that can be interpreted as true positive.
Question 14: How Should Quality Assurance Be
Maintained?
14.1: Expert Consensus Opinion
Laboratories should follow similar quality control and
quality assurance policies and procedures for EGFR and
ALK testing in lung cancers as for other clinical laboratory
assays. In particular, laboratories performing EGFR and
ALK testing for TKI therapy should enroll in proﬁciency
testing, if available.
While speciﬁc requirements and approaches may vary
somewhat from one country to another, or even betweenThe Journal of Molecular Diagnostics - jmd.amjpathol.orgdifferent accrediting organizations within one country
(eg, Joint Commission versus CAP in the United States),
the fundamental principles are conserved and retained; tests
must be properly validated, undergo regular quality control
and instrument maintenance, with monitoring of the labora-
tory environment and reagent integrity, be performed by
competent personnel following clear and informative stan-
dard operating procedures, with participation in external
proﬁciency testing procedures and subject to regular inspec-
tions by accrediting agencies.
Outside the United States, there are local initiatives for
EGFR mutation testing in, among others, Germany, Austria,
France, Italy, Greece, the Netherlands, Spain, and
Japan.11,25,240e242 In some countries, the national pathology
society has rules stating that participation in ring trials for
external quality assurance in molecular diagnostics is
obligatory. The frequency of these assessments varies from
once a year (the Netherlands, Greece, Italy) to twice a year
(Germany).
In some countries, proﬁciency testing is performed by
sending a similar sample (set) simultaneously to the partici-
pating laboratories, which report the results to the organizing
body. Subsequently, the results are compared and a concor-
dant result is a sign of adequate performance. Currently, there
are no US regulatory requirements for reporting proﬁciency
testing for EGFR and ALK assays, although proﬁciency
testing must be performed and documented, as with all
laboratory tests. The CAP offers an external proﬁciency
testing program for EGFR and KRASmutation testing, and is
developing a program for ALK FISH. CLIA regulations
require alternative assessment schemes as substitutes for
mandated successful performance on external proﬁciency
testing. When an external proﬁciency testing program is not
available, then laboratories may organize their own proﬁ-
ciency testing program by exchanging specimens with 1 or
more other laboratories at least twice per year.
In Europe, an initiative for EGFR testing has been started
in collaboration with the European Molecular Genetics
Quality Network, European Society of Pathology, European
Society for Medical Oncology, and European Thoracic
Oncology Platform, in which 10 specimens (cell lines, neutral
buffered formalin ﬁxed for 24 hours and embedded in
parafﬁn) are validated by 4 laboratories (Greece, United
Kingdom, Germany, Italy) and now run in a pilot scheme of
24 laboratories.125
In regions of the world where sample exchange is not
available, laboratories may conﬁrm accuracy of their results
by semiannual clinical chart review of tested patient speci-
mens, with the understanding that accurate determination of
EGFR and ALK status may not be determined exclusively
by beneﬁt from EGFR TKI therapy, as erlotinib/geﬁtinib
response rates for EGFR-mutated lung cancers can be in the
75% to 90% range, and the crizotinib response rates are
comparable for ALK-rearranged lung cancers.243 This may
be due to upstream or downstream factors that render the
EGFR TKI ineffective.441
Lindeman et alConclusion: Guideline Development in the Era
of Genomic Medicine
During the past decade, scientiﬁc and technological progress in
cancer genomics research has accelerated the pace of discoveries
that can be potentially translated into signiﬁcant clinical
advances for patients with major common cancers. The clinical
translation of these discoveries drives an ever-increasing need
for tumor genotyping, based on these newly established rela-
tionships between type of targetable genemutation and response
to targeted agents. In the case of the present molecular testing
guideline for selection of lung cancer patients for EGFR and
ALKTKIs, the pressing need to establish standards and provide
recommendations had to be addressed in the context of the
limitations of the literature. For many recommendations, espe-
cially more technical ones, articles reporting controlled studies
were few or absent. For recommendations shaped by survival
data, the recent and rapid clinical development of these indica-
tions, especially that of crizotinib in ALK-rearranged lung
cancers, meant that relatively limited published data were
available as compared to previous molecular testing guidelines
such as the ASCO/CAP Guideline Recommendations for
Human Epidermal Growth Factor Receptor 2 Testing in Breast
Cancer.98 In such a rapidly evolving area (and era) of medical
practice, we expect that testing guidelineswill increasingly have
to be developed on more limited published data, integrating
expert consensus opinion, with an expectation that such guide-
lineswill be updated regularly asmore rigorousmetaanalyses of
controlled studies become possible over time. Indeed, the
present guideline does not encompass less prominent but
nonetheless important testing areas, for instance, for selection of
patients for MET-targeted therapies (MET ampliﬁcation or
overexpression)244,245 and ERBB2-targeted therapies (ERBB2
mutations),246,247 and moreover, even as the present guideline
was under development, new testing indications in lung cancer
emerged, notably for rearrangements of the ROS and RET
genes.248,260,319e322 Moreover, recent technical innovations,
such as “next generation” or massively parallel sequencing,
afford the potential to detect all of these alterations, plus many
others, in1assay.157,248,249Although these technologies arevery
promising, at the present, there are still insufﬁcient published
data on the accuracy, precision, sensitivity, speciﬁcity, TAT, and
clinical validity of these methods in a clinical laboratory setting.
Whereas these next-generation sequencing-based methods are
currently not ready for routine widespread clinical imple-
mentation, their application to clinical medicine is growing
rapidly, and they may form the core technology of the next
version of these guidelines. Nonetheless, many aspects of the
current guideline are “platform-independent” or “platform-
agnostic” and, therefore, they should inform the evaluation and
implementation of emerging diagnostic tests forEGFR andALK
status based on massively parallel sequencing.
Thus, the challenges for guideline development are
mounting and include the variety of types of genetic alter-
ations to be tested, the rapidly increasing number of442clinically relevant cancer genes, the limited published
literature and testing experience associated with the accel-
erated regulatory approval of targeted drugs, and the special
issues created by the coapproval of commercial companion
diagnostic tests. Even as models for guideline development
evolve to adapt to these new factors and pressures, there
remains an ongoing clinical need for such testing guidelines
to establish and widely disseminate best practices based on
systematic and critical literature review and broad consensus
opinion from highly experienced stakeholders.
Note Added in Proof
Several new references (318e322) were added during the
page proof revision stage and are not cited in numeric order.
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Disclaimer
Clinical practice guidelines and consensus statements reﬂect
the best available evidence and expert consensus supported in
practice. They are intended to assist physicians and patients in
clinical decision making and to identify questions and settings
for further research. With the rapid ﬂow of scientiﬁc infor-
mation, new evidencemay emerge between the time a practice
guideline or consensus statement is developed and when it is
published or read. Guidelines and statements are not contin-
ually updated and may not reﬂect the most recent evidence.
Guidelines and statements address only the topics speciﬁcally
identiﬁed therein and are not applicable to other interventions,
diseases, or stages of diseases. Furthermore, guidelines and
statements cannot account for individual variation among
patients and cannot be considered inclusive of all proper
methods of care or exclusive of other treatments. It is thejmd.amjpathol.org - The Journal of Molecular Diagnostics
Lung Cancer Molecular Testing Guidelinesresponsibility of the treating physician, relying on independent
experience and knowledge, to determine the best course of
treatment for the patient. Accordingly, adherence to any
practice guideline or consensus statement is voluntary, with
the ultimate determination regarding its application to bemade
by the physician in light of each patient’s individual circum-
stances and preferences. CAP, IASLC, and AMP make no
warranty, express or implied, regarding guidelines and state-
ments and speciﬁcally exclude any warranties of merchant-
ability andﬁtness for a particular use or purpose.CAP, IASLC,
and AMP assume no responsibility for any injury or damage
to persons or property arising out of or related to any use of this
statement or for any errors or omissions.
In formulating recommendations for molecular testing in
lung cancer, CAP, IASLC, and AMP considered these
tenets of guideline development, emphasizing review of
data from appropriately conducted and analyzed clinical
trials. Practice guidelines are not intended to supplant
physician judgment with respect to particular patients or
special clinical situations. The literature and expert review
process was directed toward evaluating and selecting the
best science for the best possible patient care; a cost analysis
was not performed for this guideline.Supplemental Data
Supplemental Material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2013.03.001.
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